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SESSION 1
(Chairman: K.E. Halnan)
The monoclonal antibody revolution
J.H. Humphrey
Royal Postgraduate Medical School, London, UK
Many attempts (some successful) have been made
in the past to obtain tumour-specific antibodies by
immunizing animals with tumour cells or extracts
followed by removal by absorption of antibodies
reactive with the corresponding normal cells.
However, the amount of residual specific antibody
represented a minute proportion of the remaining
Ig and other proteins present in an antiserum.
Specificity of labelling was difficult to achieve, and
the preparations were liable to be highly
immunogenic.
Monoclonal antibodies have changed all this. A
large proportion of the Ig secreting cells in a
sample from an immunized mouse or rat can be
fused with myeloma cells selected to possess very
active potential Ig-secretion machinery but by
themselves secreting little or no Ig of their own. If a
reasonably simple screening method is available, it
is possible to select hybridoma secreting antibodies
with a desired specificity, even if these occurred
only rarely in the starting population. It is
becoming possible to predict which determinants on
a complex antigen will be most immunogenic, and
to design antigens so as to elicit antibodies against
attached chosen structural determinants (when these
are known).
Course Organisers: A.A. Epenetos & K.E. Halnan,
Royal Postgraduate Medical School and Hammersmith
Hospital, London W12 OHS, UK.
Course Secretary: A. Freemantle, Department of
Medical Physics, Royal Postgraduate School and
Hammersmith Hospital, London W12 OHS, UK.
The organisers are grateful to the Imperial Cancer
Research Fund for their support.
Although it is not possible to predict in advance
what will be the Ig subclass or the affinity for the
selected antigen of any particular hybridoma, with
persistence and some luck hybridomas secreting Ig
of the desired subclass and affinity can be obtained.
The essential feature of monoclonal antibodies is
their goodness of fli with the shape of quite small
tertiary structures exposed at the surface of the
antigen. This allows exquisite specificity, but may
result in unexpected cross-reactions.
SESSION 2
(Chairman: S.E. Order)
Juggling with immunoglobulin genes
L. Luzzatto
Department ofHaematology, Royal Postgraduate
Medical School, London, UK
Differentiation of individual cell types in the course
of ontogenesis is associated with differential
expression and repression of genes. In the majority
of cases this is brought about by a variety of
complex regulatory mechanisms operating in cells
that have identical genomes. In this respect, the
regulation of immunoglobulin (Ig) genes appears to
be exceptional, because it is effected by the
construction of functional genes from DNA regions
that are separate from each other in the germ-line
genome. The assembly of the Ig genes takes place
through an orderly sequence of events which are
part of the developmental programme of lymphoid
cells of the B-lineage. This process makes each
individual clone of B cells uniquely different from
every other B cell, and this is precisely what has
made the development of monoclonal antibodies
possible. Very recently it has become clear that a
similar process underlies the assembly of the T cell
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receptor during the ontogenesis of T cells. The
molecular basis for Ig genes assembly can be
defined, with due consideration to the phenomena
of allelic exclusion and class switch. The analysis of
Ig gene rearrangements has turned out to be
especially useful for the characterization of
leukaemic cell clones. Whereas most characteristics
of differentiated cells are appropriately regarded as
phenotypic, the Ig produced by B cells and the
receptors produced by T cells correspond to genetic
changes which have taken place in them at the
somatic level. This is a new concept in somatic cell
genetics, and it is likely to offer a useful model for
an understanding of the role of somatic mutation
and recombination in cell differentiation and
possibly in oncogenesis.
Progress in the development of human monoclonal
antibodies
K. Sikora
Ludwig Institutefor Cancer Research, Cambridge,
UK
Human monoclonal antibodies against molecules
expressed on tumour cell surfaces have proven
difficult to construct. Their advantage in revealing
new antigenic determinants and their potential for
repeated clinical use in therapy have resulted in
considerable investment in their production. Major
problems include the slow growth rate of human
myeloma lines, their low hybridisation frequency
and their continued secretion of immunoglobulin
coded for by genes of the parental myeloma,
resulting in mixed immunoglobulins. There are now
over 15 lines available for hybridisation.
We have obtained biopsies from 240 patients
with a variety of tumour types and fused
lymphocytes from either regional lymph nodes or
within the tumour with the lymphoblastoid line
LICR.LON.HMy2. Cloned hybrids were obtained
from a total of 37 patients. Hybridomas grew
rapidly and could be tested for new immuno-
globulin secretion. Antibodies were screened by
binding activity on the most appropriate tumour
cell line and subsequently by immunofluorescence.
Twelve antibodies have been found to bind to cell
surface antigens on tumour cell lines. Two were
evaluated for radioimmunolocalisation. Successful
images were obtained in patients with glioma and
carcinoma of the bronchus. Recent advances in
peptide immunisation, both in vivo and in vitro,
may provide new ways to produce human
antibodies of defined specificity.
Radioactive antibodies in cancer detection and
therapy: Experimental and clinical findings
D.M. Goldenberg
Center ofMolecular Medicine and Immunology,
University ofMedicine and Dentistry ofNew Jersey,
Newark, NJ, USA
Radioimmunodetection is the method of cancer
diagnosis using radiolabelled tumour associated
polyclonal or monoclonal antibodies. The standard
radionuclide used to date has been 1-131. 111In
and Tc-99 have recently been introduced but as yet
have undesirable RES accretion. Studies at our
centre with conventional goat and murine
monoclonal antibodies against carcinoembryonic
antigen (CEA), alpha-foetoprotein (AFP), human
chorionic gonadotrophin (HCG), prostatic acid
phosphatase (PAP), colon-specific antigen-p (CSAp)
and Reisfeld's high mol. wt melanoma antigen
(9.2.27) have a sensitivity of 90%. In 11 out of 51
patients with colorectal cancer, occult cancer was
detected and was later confirmed by other methods,
achieving a lead time of up to 40 weeks. Radio-
immunodetection revealed all tumours whilst CAT
and NMR scanning disclosed 37.5% and 50%
respectively. Image resolution ranged between 1.5-
2.0cm tumours. In pancreatic cancers, single
photon emission tomography improved imaging.
1311 anti-CEA IgG was able to retard tumour
growth of GW-39 human colonic carcinoma
xenografts in animals. Therefore, a clinical Phase
I/II trial of radioimmunotherapy has begun.
Patients will receive between 25-75mCi 1311
labelled anti-CEA or anti-AFP antibodies weekly
for 4 weeks.
Current results indicate a blood T- of 24-36h
and the formation of circulating immune
complexes.
Antibody guided irradiation of cancer
S.E. Order
Department ofRadiation Oncology, The Johns
Hopkins Oncology Centre, Baltimore, MD, USA
Radiolabelled 1311 antiferritin will selectively
target tumours that synthesise and secrete ferritin,
hepatoma, Hodgkin's disease, etc. In an H42E rat
hepatoma, the 'biologic window' that allows selec-
tive targeting without normal tissue uptake has
directly correlated with neovasculature and ferritin
synthesis. In dose escalation studies in hepatoma
tumour saturation was determined by volumetricABSTRACTS 643
calculations (mean vol. 1000-1500ml) and radio-
active concentration counts (6-12 pCimg-1) and
has shown that 30 mCi (10 mCi mg-1 IgG)
saturated the tumour. The 4 day tumour effective
half life led to a second dose of 2OmCi and achieved
a 10-12Gy tumour dose. The toxicity was
thrombocytopenia. Volumetric reconstruction of
serial CAT scans allowed quantitation of tumour
volumes for evaluation of remission. Administration
of antiferritin from different species was associated
with different tumour effective half lives (rabbit, pig,
monkey, bovine 3-4 days) (goat, sheep 2 days), and
avoided anti-antibody reactions. In a 105 hepatoma
patient experience 48% of the patients had at least
partial remission, and 4% of these patients complete
remission. One patient remains disease-free in
complete remission, 3 years and 3 months, and
another patient in partial remission, 5 years and 5
months. Fifteen percent of remitted patients are
beyond 2 years.
In Hodgkin's disease, in MOPP-ABVD failures,
1311 antiferritin has a 40% partial remission rate
and a 70% remission of B symptoms. Thrombo-
cytopenia occurred earlier due to limited marrow
reserve.
SESSION 3
(Chairman: A.J. Munro)
Monoclonal antibodies to leucocyte and thymic
antigens
M.A. Ritter
Department ofImmunology, Royal Postgraduate
Medical School, London, UK
Monoclonal antibodies to molecules on the cell
surface membrane of human leucocytes have
provided much information on developmental and
functional subsets of haemopoietic cells, as well as
on the function of the molecules themselves. For
example, for T lymphocytes the identification of the
cell surface molecules TI, T3, T4, T6, T8, and Ti1
has made it possible to study intra-thymic T cell
ontogeny, to identify functionally mature sub-
populations of recirculating peripheral T
lymphocytes and to study some of the molecular
events involved in T cell activation. Clinically,
monoclonal antibodies to leucocytes have been
useful both in assessing immune status and in
analysing haemopoietic malignancies. Normal
haemopoietic differentiation depends upon an inter-
action between the progenitor cells and their micro-
environment. We have recently raised monoclonal
antibodies to molecules in/on the epithelial com-
ponent of the human thymus microenvironment,
and using these can identify several cell surface and
secretory products that may be responsible for
progenitor/lymphocyte positioning, migration and
differentiation within the thymus. We are currently
using these reagents to analyse the thymic micro-
environment in myasthenia gravis. Preliminary data
indicate that whereas in patients with thymic hyper-
plasia it is the subcapsular/medullary epithelium
that is proliferating, in thymoma cases it is the
cortical epithelium that is involved in the neoplasia.
(Work in collaboration with: Drs J. Newsom-
Davies, N. Wilcox, J. Janossy, Royal Free Hospital,
London; Dr H.-J. Schuurman, University Hospital,
Utrecht).
Breast epithelial differentiation antigens
J. Burchell, J. Bartek & J. Taylor-Papadimitriou
Imperial Cancer Research Fund, London, UK
In the haemopoietic system, the study of normal
differentiation has greatly aided in the management
of many leukaemias. In an attempt to apply a
similar approach to the study of breast carcinomas,
the differentiation of mammary epithelial cells is
being investigated. To facilitate this study, mono-
clonal antibodies have been produced to (1) human
B casein, a milk protein which is a unique product
of terminally differentiated breast epithelium, (2)
cytokeratins, which are expressed exclusively by
epithelial cells, the profile of expression being
characteristic of a specific epithelial cell type, and
(3) a large mol. wt mucin-like component present in
human milk fat globule which is recognised by
monoclonal antibodies HMFG-1 and 2. The
HMFG-1 antigen is highly represented on this
mucin and on lactating breast, and its presence has
been associated with the decrease growth potential
of normal breast epithelium in vitro. In contrast, the
HMFG-2 antigen is poorly represented on the
mucin, but is strongly expressed by most breast
cancer cell lines and ductal carcinomas and its
presence in the serum of advanced breast cancer
patients may be associated with a bad prognosis.
These antibodies are now being used to charac-
terise breast epithelial cells in vitro cultured on
plastic and in collagen gels. Additionally, the
HMFG-1 and 2 antibodies have been found to have
practical uses in the clinic including (1) the identifi-
cation of carcinoma cells in serous effusions, (2) in
in vivo imaging of carcinomas, especially ovarian,
and (3) targeting of therapeutic doses of radiation.644 ABSTRACTS
SESSION 3 (Open Papers)
(Chairman: A.J. Munro)
Enzyme amplification and oncological markers
C.H. Self
Department ofChemical Pathology, Royal
Postgraduate Medical School and Hammersmith
Hospital, London, UK
Enzyme amplification provides a means of
developing highly sensitive and rapid assays for
oncological markers. The assays may be made
colorimetric and thus simple to read.
Amplification is achieved by causing the enzyme
to be determined to produce a catalytic activator
for a secondary enzyme system, the activity of
which is measured. Thus the catalytic effect of the
enzyme to be determined is multiplied by the
catalytic effect of the activator it produces. The
measured activity is correspondingly large.
The enzyme activity which is amplified may be
either that of the analyte itself, when this has a
suitable enzymatic activity, or that of an enzyme
conjugate in, for example, ELISA systems. The
former case has been demonstrated by the appli-
cation of enzyme amplification to a monoclonal
antibody-based capture assay for placental alkaline
phosphatase. This has resulted in a much more
sensitive and rapid assay compared to conventional
methods. The application of enzyme amplification
to ELISA systems has meant that a very wide range
of materials of oncological importance may now be
assayed by amplified systems. The advantages of
this approach have been shown, for example, by the
determination of prostatic acid phosphatase by
enzyme amplified ELISA.
Application of monoclonal antibodies to the
characterisation of acute leukaemias.
E. Matutes, A. Parreira, C. Andrews, V. Moss,
A. Karabyn & D. Catovsky
MRC Ieukaemia Unit, Royal Postgraduate Medical
School, London, UK
Immunological analysis of haemopoietic precursors
by using cell lineage specific monoclonal antibodies
(McAb) has led to a better recognition of leukaemic
cells and has increased the diagnostic possibilities of
otherwise unclassifiable leukaemias. In this study we
describe the phenotypic characterisation of blast
cells from a series of over 200 patients with acute
leukaemia and blast transformation of chronic
granulocytic leukaemia (CGL) and myelofibrosis
(MF) by an indirect immunofluorescence technique
using the following McAb: (1) LICR-LON 10-
antiglycophorin A- and GERO - against the RBC
group Gerbich - to recognise erythroid cells; (2)
AN51-antiplatelet glycoprotein (gp) Ib-; C17-
antiplatelet gp IIIa and J15-antiplatelet gp Ilb/IIIa
- to identify megakaryocytic precursors; (3) My9
against myeloid and monocytic cells - and 3C5 -
reactive with early myeloid and lymphoid percursor
cells; (4) terminal deoxynucleotidyl transferase
(TdT); J5 (anticommon ALL); anti-B4 (early B-
cells); 3A1 (anti-p40) and OKT17, to identify early
B and T cell lymphoblasts. Data will be presented
on the value of this approach in: (a) the charac-
terisation of some 'undifferentiated' leukaemias as
proliferations of erythroid and megakaryocytic
precursors; (b) the identification of leukAemias with
mixed cellular components (e.g. myeloid and
megakaryocytic, etc.); (c) the distinct reactivity of
the McAb My9 and 3C5 in the various types of
acute myeloid leukaemia according to the FAB
classification, e.g. My9+, 3C5+ in myelobasts (Ml)
and My9+, 3C5- in monoblasts; (d) the classifi-
cation of the T cell malignancies according to the
reactivity with TdT, 3A1 and OKT17 in early
thymic (TdT+, 3A1+, OKT17-); thymic (TdT+,
3A1+, OKT17+) and post-thymic (TdT-, 3A1-,
OKT17+) proliferations.
Immunohistochemical localisation of hPLAP, CA
125 and CEA in normal and neoplastic human
tissues and the foetus
E.J. Nouwen, M.W. Eerdekens, T.W. Briers,
D.E. Pollet & M.E. De Broe
Department ofNephrology-Hypertension, University
Hospital ofAntwerp, Edegem, Belgium
Human placental alkaline phosphatase (hPLAP),
CA 125 and CEA were localised on adjacent paraffin
sections using monoclonal antibodies (E6, OC 125
and the Hybritech antibody, respectively) and an
indirect avidin-biotin-peroxidase staining procedure.
On 8 malignant lung tumours, 4 were positive for
hPLAP, 6 for CA 125 and 7 for CEA. All 13
normal lungs were positive for the three antigens.
hPLAP staining was present in the respiratory
bronchioli and alveoli. CA 125 was observed in the
trachea, bronchi, respiratory glands, terminal
bronchioli and pleural mesothelium. CEA staining
was present in the trachea, bronchi, respiratory
bronchioli and alveoli. In the foetal lung, hPLAP
could not be demonstrated. CA 125 was present in
the foetal trachea, bronchi, respiratory glands andABSTRACTS 645
mesothelium. On 23 malignant ovarian tumours, 18
were positive for hPLAP, 22 for CA 125 and 9 for
CEA. CA 125 staining was in general more
abundant than hPLAP staining. Two of 13 normal
ovaries were positive for hPLAP and 12 for CA
125, whereas CEA staining was absent. CA 125
staining in the normal ovary was present in the
surface epithelium, local proliferations of this
epithelium, invaginations and germinal inclusion
cysts. hPLAP staining was observed only in some
of the germinal inclusion cysts. The foetal ovary
was positive for hPLAP, but negative for CA 125
and CEA. Normal tuba was positive for hPLAP
and CA 125, but negative for CEA. On 18
malignant gastrointestinal tumours, 10 were positive
for hPLAP, 6 for CA 125 and 18 for CEA. hPLAP
and CA 125 staining was absent in 12 normal
gastrointestional tissues, but CEA staining was
always present. The foetal oesophagus was positive
for CA 125. On 7 malignant breast tumours, 1 was
positive for hPLAP, 6 for CA 125 and 4 for CEA.
Immunoreactivity of monoclonal anti-melanoma
antibodies iodinated by different methods
S. Matzku & H.J. Sinn
Institute ofNuclear Medicine, German Cancer
Research Centre, Heidelberg, FRG
Six monoclonal antibodies (MAbs) were iodinated
using chloramine T, IODO-GEN or N-bromo-
succinimide to achieve increasing levels of iodine
substitution. Immunoreactivity was characterised by
sequential absorption, by Lineweaver-Burk-type
extrapolation to binding at infinite antigen
(melanoma cell) concentration, and by Scatchard
plots. Our findings can be summarised as follows:
(1) Immunoreactivity depended on iodine substi-
tution ratios rather than on the iodination method,
provided that mild reaction conditions were
adopted.
(2) MAbs displayed considerable individuality with
respect to the level of substitution they tolerated.
(3) Iodination was found to be an all or none effect
reducing the proportion of antibody molecules
binding at antigen excess, or a gradual effect
reducing binding affinity. Reduced immuno-
reactivity was clearly reflected by a poor
performance of labelled MAbs in vivo, e.g. in
immunoscintigraphy.
lodination of monoclonal antibodies for diagnosis and
radiotherapy using a convenient one vial method
H. Haisma, J. Hilgers, W. Den Otter &
V.R. Zurawski, Jr.
Centocor, Inc., Malvern, USA, Netherlands Cancer
Institute, Amsterdam, and Institute ofPathology,
Utrecht, The Netherlands
The use of monoclonal antibodies for diagnosis
and therapy of cancer is well established. 1231 and
1311 are the isotopes of choice in most cases. The
use of radiolabelled antibodies is restricted to
specialised centres for the iodination of antibodies is
rather complicated. We have developed a
convenient system using a one vial method for
iodination of antibodies for diagnosis and therapy.
A vial previously coated with iodogen is used as a
reaction vessel. Iodination and separation of bound
and free iodine using AGI-X8 (Dowex) ion
exchange resin are both accomplished in this vial.
Using four different monoclonal antibodies
reactions incorporated 90+4% of the iodine which
was added. Approximately 90% of labelled antibody
was recovered in each case. The monoclonal anti-
body OC125 was labelled to specific activities up to
25 mCi mg-' with immunoreactivities of 82+2%
using 1251 and 66+5% using 1311. As the radio-
iodination is done in one sealed vial and takes
<Omin, this procedure is safe and can be
performed in any nuclear medicine laboratory. The
final product, which is sterile and pyrogen-free, is
suitable for diagnostic and radiotherapeutic
applications. We anticipate that this method has
great implications for the use of iodinated anti-
bodies for imaging and therapy making radio-
immunodetection and antibody guided radiation
therapy less restricted to specialised centres.
NMR relaxation time in nude mice bearing human
colorectal adencarcinoma injected with MoAb 19.9
coupled with gadolinum-DTPA as contrast agent
C. Curtet1, J. Grzyb2, C. Tellierl, J.Y. Douillard'
& J.F. Chatal1
1INSERM U.211, UER Medecine & 2CEA de
SACLAY, Nantes, France
Gadolinium-DTPA MoAb 19.9 are presently being
investigated for their potential use as tumour-
specific (NMR) imaging agents.
The strongly paramagnetic gadolinium complex
reduces hydrogen proton relaxation. The metal ion
(Gd3+) needs to be chelated with a suitable ligand
(DTPA) to decrease the toxicity, and to enable
coupling with MoAb 19.9 which is direct against
specific tissues (human colon adenocarcinoma SW
1116, HT 29, and HRT 18).
The effect of the paramagnetic compound on
proton relaxation T1 and T2 was measured in646 ABSTRACTS
aqueous solutions for different concentrations at 60
and 90 MHz using the Bruker NMR spectrometer.
Pharmacokinetics were performed with 153 Gd
labelled compound (0.3 yuCijug ') to study the
biodistribution at days 1, 2 and 5. The best binding
in the tumour was observed at days 1 and 2.
Finally, we injected Gd-DTPA MoAb 19.9 ((Gd)
1 mM, (DTPA) 1 mM, (MoAb) 0.06mM) in mice
bearing HRT 18 tumour.
A 20% difference was noted relative to controls.
A prognostic index for primary breast cancer
incorporating staining with monoclonal NCRC 11
I.O. Ellis, M.R. Williams, J.H. Todd, C.W. Elston
& R.W. Blamey
Department ofHistopathology, Queens Medical
Centre, and City Hospital, Nottingham
A monoclonal antibody NCRC 11 has been raised
against breast carcinoma. It has a similar immuno-
histological staining distribution to epithelial
membrane antigen (EMA).
The prognostic importance of monoclonal
staining with NCRC 11 antibody has been
demonstrated on a series of 126 primary tumours.
A prognostic index for primary operable breast
cancer has been previously described. This is
dependent on size, grade and lymph node stage of
the primary tumour.
In this study we confirm this prognostic power
on 379 tumours and further investigate the relation-
ship with grade, ER, lymph node status and size of
primary tumour.
NCRC 11 monoclonal staining is found to relate
to both grade and ER (intrinsic factors) but not to
stage or size (time dependent factors). It has
independent prognostic power and has been
incorporated into a new prognostic index.
SESSION 4
(Chairman: J.P. Lavender)
Radiochemistry of DTPA-coupled monoclonal
antibodies
D.J. Hnatowich
University ofMassachusetts Medical Center,
Worcester, MA, USA
The majority of investigators studying radiolabelled
monoclonal antibodies for diagnosis and therapy of
cancer label with radioisotopes of iodine. An
attractive alternative approach is to first covalently
attach a strong chelating group such as diethylene-
triaminepentaacetic acid (DTPA) so that the anti-
body may be labelled later with one of several
metallic radionuclides. Using antibodies coupled
with DTPA via the cyclic anhydride, we have
evaluated the chemistry of labelling with three
radionuclides: 1"1In and 99mTc for tumour
diagnosis and the beta-ray emitting 90Y for tumour
therapy. The important property of label stability in
37°C serum was determined in vivo and in vitro by
methods involving high performance liquid
chromatography, affinity and open-column gel
filtration chromatography.
Our results show that the attached DTPA groups
do not dissociate from the antibody in serum
environments. Furthermore, when DTPA-coupled
antibodies are labelled with either 11'In or 90Y, the
label is unstable only to transcomplexation to trans-
ferrin. The rate of this dissociation is about 8-9%
of the activity in serum per day. When the DTPA-
groups on antibodies are labelled with 991Tc, a
similar transcomplexation of label to serum
proteins is observed: however, in this case, the label
is also unstable towards oxidation to pertechnetate.
Biodistribution and pharmacokinetics of In-111
labelled monoclonal antibody F(ab')2 fragments in
patients
P.W. Doherty
University ofMassachusetts Medical Center,
Worcester, MA, USA
We studied 14 patients who had known sites of
tumour, with the antibody 19-9 labelled with
I1 1In, usingthecyclicanhydride approach. Following
injection of 1 mg of the fragments labelled with 1-
2mCi of 1I1In, biological clearance was evaluated
by whole body scanning and organ uptake was
quantitated using attenuation correction. Serial
blood and urine samples were examined by HPLC
and affinity chromatography to determine the
chemical form of activity. The clearance of radio-
activity from serum was biphasic with a T- of 2
and 19h. Whole body clearance was 160h with
urine loss predominating at 0.26% of injected dose
excreted per hour. Regionally, 20% of the activity
was present in the liver and 10% in the kidneys
with maximum levels occurring at 24h and did not
decrease much over time. Translocation of activity
to transferrin occurred at a rate of 9%day-1 and
antigen antibody complex formation was not a
major problem. Good quality images of tumour
uptake were obtained in 8 of 12 sites, most obviousABSTRACTS 647
at 48h. Those sites in which uptake was not seen
were liver metastases. SPECT imaging was helpful
in providing better localization information.
Overall, the labelled antibody is quite stable in vivo
and the distribution of the radioactivity is
equivalent to the distribution of the antibody. The
major site of catabolism appears to be the liver
from which the 111In is not released to any great
extent. These observations have implications for
those considering this approach to therapy.
123I labelled antibodies - state of the art
K.E. Britton and M. Granowska
Department ofNuclear Medicine, St. Bartholomew's
Hospital, London, UK
The monoclonal antibody is a homogeneous
gamma globulin with many tyrosine radicals
suitable for iodination using the gentle techniques
refined for radioimmunoassay over many years.
1311 is unsuitable as the iodine label because its
beta emission and long half-life cause high patient
radiation when given in a dose sufficient to give
good imaging sensitivity and its use should be
limited to therapy. 123I with no beta emission, 13 h
halflife and 16MeV gamma ray energy is ideal for
imaging with the gamma camera. It is becoming
more widely available and per MCi is half the price
of IIIIn, the alternative label. It has been shown
that 123I labelled monoclonal antibodies preserve
their immunoreactivity whereas chelation for I1IIn
labelling may cause cross-linking of antibodies,
leading to high liver uptake and reduced immuno-
reactivity. The kinetics of antibody uptake favour
a high sensitivity, short-lived radionuclide which
gives a good signal. Our original technique of
subtracting an early image from a later one has
been refined through kinetic analysis of serial
images with probability mapping. On the assump-
tion that tissue background is decreasing with time
and tumour uptake is increasing with time, serial
images may be compared pixel by pixel and the
frequency distribution of activity plotted. Using a
least squares technique the clusters ofpixels showing
significant positive or negative deviation with
time may be identified and the areas of significant
change, at, for example, the P<0.001 plotted on
a map as a contour over the original data. This
objective approach is needed to define that an
abdomen is really clear or not of recurrence.
Clinical decisions based on antibody guided scanning
R.H.J. Begent, F. Searle, A. Green &
K.D. Bagshawe
CRC Laboratories, Charing Cross Hospital, London,
UK
Radioimmunoscintigraphy is capable of locating a
variety of malignant tumours. Its place in clinical
practice depends on its performance in defined
clinical situations where the result determines a
decision about patient management.
Since 1980 we have studied patients with a raised
serum tumour marker concentration in whom the
site of disease was not known but in whom
resection of localised tumour might be beneficial.
Patients with drug resistant choriocarcinoma and
raised serum human chorionic gonadotrophin
(hCG) were studied with antibody to hCG. Similar
patients with germ cell tumours and raised serum
hCG or alphafoetoprotein (AFP) received antibody
to hCG or AFP as appropriate. Patients with raised
serum carcinoembryonic antigen (CEA) values after
apparently complete resection of primary colorectal
cancer received antibody to CEA.
Radioimmunoscintigraphy was able to dis-
criminate between localised and disseminated
disease and improved the selection of patients for
surgery. In some instances the method detected
tumour when conventional imaging failed. In these
diseases which are usually disseminated at the stage
studied, it was possible to select - 10% with
localised disease who have obtained sustained
complete response as a result of surgical resection.
SESSION 4 (Open Papers)
(Chairman: J.P. Lavender)
Monoclonal antibody imaging as an adjunct to
radiographic CT in abdominal metastases
P.J. Moldofsky, N.D. Hammond, R.E. Exten,
R.A. Gatenby & G.J. Broder
Fox Chase Cancer Center and Jeanes Hospital,
Philadelphia, PA, USA
In imaging over 50 patients with 131I labelled
F(ab')2 fragments of monoclonal antibodies
directed against colorectal carcinoma cell surface
antigens we have identified 5 areas of potential
utility for this diagnostic method to provide
information complementary to that provided by
radiographic CT. Approximately 100-500 ug of
F(ab')2 fragments are labelled by the iodogen648 ABSTRACTS
method with approximately 37MBq (1 mCi) 1311.
I.v. administration to patients with known or
suspected colorectal carcinoma is followed by daily
imaging for up to 7 days. Patients also undergo
radiographic CT scanning and either a CT-guided
biopsy or surgical biopsy for pathology and
immunoperoxidase staining for the colorectal
antigen.
Patients have been identified in 5 categories of
diagnostic utility where the antibody images
provided information beyond that available from
CT: (1) Small disease: lymph nodes harbouring
microscopic metastases, normal in size (1 cm) on
CT, have been detected by antibody imaging. (2)
Differentiation of post-operative change from
recurrent tumour: despite little change in soft tissue
mass at the primary operative site on CT scans 3
months apart, antibody scan indicated recurrent
tumour, confirmed at surgery. (3) Localization of
recurrence in patients with no identifiable disease
by CT but rising serum CEA. (4) Differentiation of
types of tumour metastasis in patients with more
than one, or unknown, primary. (5) Quantitative
evaluation of localization of antibody in tumour,
for therapeutic applications. While most sites of
disease were localized by CT scans, we have
identified 5 categories of additional information
provided by the antibody scans that have
influenced clinical decisions in these patients.
Imaging of cutaneous T-cell lymphoma (CTCL) with
"'In and 131I labelled T101
J.A. Carrasquillo, J.M. Mulshine, J.C. Reynolds,
A.M. Keenan, P.A. Bunn, K.A. Foon,
R.W. Schroff, A.F. Gazdar, P. Perentesis,
M. Horowitz & S.M. Larson
CC, NCI, BRMP, National Institutes ofHealth,
Bethesda, MD, USA
TIOI is a murine monoclonal antibody (MOAB),
IgG2a directed against a pan T-cell antigen
presentinhighconcentration inCTCL. 111Inlabelling
(5mCi, 1 mg) was performed by a modification of
the Krejcarek method (Hybritech, Inc.): 1311
labelling (2mCi, 1 mg) was performed via the
chloramine T method. Six patients received 1 mg
111In TI01 and 3 patients received 1mg 1311 TIOI
i.v. by a 2-h infusion. By 24h all patients receiving
11"In T101 showed uptake in involved nodes as
well as previously unsuspected nodes. Nodes as
small as 5 x 5mm were visualised. Skin plaques (6
patients) were negative whereas erythroderma (1
patient) was positive on scan. In addition,
prominent liver, spleen and bone marrow uptake
was visualised and persisted on serial scans. 1311
TIOl showed minimal nodal concentration in 1
patient and none in the other 2 patients. Although
early images showed prominent liver, spleen and to
a lesser extent bone marrow uptake, serial images
showed rapid clearance of 1311 from these organs.
One patient received both 1311 and 1"'In-labelled
TIOI with no localisation in involved nodes with
1311 label but prominent areas of nodal uptake and
skin (erythroderma) with "'1In TIOI (4 days later).
Plasma clearance was rapid for all preparations
with <20% in the plasma volume by 2h post-
infusion. Whole body retention was prolonged for
"'In versus 1311 TI01 (T- of >9d vs <2d). Rapid
dehalogenation was observed, with free 1311
excreted in the urine. No toxicity was observed.
Modulation of antigen from circulating cells, skin
and nodes was seen. The study shows the feasibility
of imaging CTCL with "'1In TIOI and shows
major differences in biodistribution when compared
to 1311 TIOI.
Radioimmunoscintigraphy (PLANAR+SPECT) as a
method in the follow-up of ovarian cancer patients
N. Pateiskyl, K. Philipp', H. Bergmann2,
G. Hamilton3 & J. Burchell4
1Jst Department ofGynaecology and Obstetrics,
2Department ofNuclear Medicine, 3Ist Department
ofSurgery, University of Vienna, Austria; and
4Imperial Cancer Research Fund, London, UK
More efficient methods are needed for screening
after recurrent disease of ovarian cancer to improve
the post-operative treatment and therefore the
survival of these patients. Radioimmunoscinti-
graphy using monoclonal antibodies against a
differentiation antigen (HMFG2) was performed in
25 patients, each of them having an ovarian
tumour. The results were satisfactory, thus we
decided to scan patients with ovarian cancer
routinely as part of other investigations performed
in the post-treatment follow-up of these patients.
Each patient underwent a second look operation to
assess if there was residual disease. Radioimmuno-
scintigraphy, including Single Photon Emission
Computed Tomography (SPECT) was able to
detect malignant lesions in some patients which
could not be found by other non-invasive
investigations. In these patients, the decision on
further management was based upon the radio-
immunoscintigraphy results. We conclude that
radioimmunoscintigraphy, including SPECT, using
an appropriate monoclonal antibody such as
HMFG2, is able to improve the management of
patients with ovarian cancer.ABSTRACTS 649
1231-NDOG2 anti-placental alkaline phosphatase
imaging of ovarian tumours
E.R. Davies', J.O. Davies2, P.C. Jackson3,
K. Howe2. E.M. Pitcher3, C.S. Sadowski4,
G.M. Stirrat2 & C.A. Sunderland2
Departments of 'Radiodiagnosis, 2Obstetrics and
Gynaecology, 3Medical Physics and 4Pharmacy,
United Bristol Hospitals, UK
The use of radiolabelled monoclonal antibodies
offers important opportunities for diagnosing and
treating tumours. Confidence in these potential uses
requires understanding of the biodistribution of the
radiopharmaceutical in tumour-free and tumour-
bearing regions. Twenty patients with suspected or
surgically confirmed ovarian carcinoma were
studied with a monoclonal antibody (NDOG2)
labelled with 123I and directed against placental
alkaline phosphatase. Scans of the trunk were done
10min, 4h and 20h after giving 250ug of labelled
antibody i.v. Changes in the biodistribution of
radioactivity were monitored and compared with
identical studies in 5 patients with carcinoma of the
breast who had tumour free abdomina and pelves.
Tumour sites were identified in 16 patients (80%)
but the uptake patterns varied because of renal
clearance and redistribution of radioactivity from
the blood pool to other compartments. Known
tumours were not shown in the liver (1), para-aortic
lymph nodes (1) and peritoneum seedlings (2). False
positives arose because of intestinal activity (2) and
subtraction artefact (1). A whole body dose of
16.3 pSv MBq-1 was calculated. The diagnostic
potential of the technique is limited by the
variability of PLAP expression in tumours. The
agent has not been used for therapy at present.
Radioimmunolocalisation of the c-myc onocogene
product in patients with lung cancer
S.Y.T. Chan, A. Ritson & K. Sikora
Ludwig Institutefor Cancer Research, MRC Centre,
Cambridge, UK
We have studied the clinical application of a set of
monoclonal antibodies raised by peptide immunisa-
tion against fragments of the human c-myc
oncogene product. One such antibody, Myc- 1
CT14, was derived against the 14 amino acid
carboxy terminus of the c-myc. This mouse
monoclonal antibody (an IgGlK) was grown in
ascites and purified. One milligram of antibody
radiolabelled with 1 mCi 1311 was injected i.v. into
10 patients with primary lung cancer and 10
patients with lung metastases from tumours arising
in different organs. There was selective uptake of
Myc-l CT14 at the primary tumour site of all 10
patients with carcinoma of the bronchus suggesting
a large quantity of the c-myc oncoprotein in these
areas. Metastases derived from bronchial carcinoma
did not take up the antibody. Ten patients with
pulmonary metastases arising from sites other than
lung also failed to take up Myc-l CT14. The
cellular location of the c-myc oncoprotein is known
to be nuclear and we conclude that detection in
large primary tumours was due to cell death and
subsequent release of the protein. Such antibodies
may be of use in monitoring tumour load and
response to therapy.
Antibody guided tumour detection using 131I labelled
F(ab')2 fragments of an anti-CEA moab
P. Riva" 2, G. Paganelli"2, G. Cacciaguerra1,
G. Gentili', L. Marri', V. Tison', M. Marangolo'
& D. Amadori'
1Istituto Oncologico Romagnolo and 2Servizio di
Medicina Nucleare, Ospedale M. Bufalini, Cesena,
Italy
Twenty-eight patients with primary and/or
metastatic gastro-intestinal cancer were studied by
external scintigraphy after i.v. injection of 13li-
labelled F(ab')2 fragments of a monoclonal antibody
raised against carcinoembryonic antigen (FO23C5 -
Sorin Biomedica). Primary tumours were seen in 11
out of 11 patients. Metastases were seen in 60-100%
of cases depending on the different organs
investigated.
Best images were obtained at 72, 96 and 120h.
Lesions detected were confirmed either by
conventional techniques such as X-ray, CT, ultra-
sound, or by surgical removal. Where possible the
in vivo results were confirmed in vitro by immuno-
peroxidase staining of surgically removed tissues. As
a negative control, patients having positive scans
received an equal amount of a non-specific F(ab')2
fragment (225.28S). No positive scans were obtained
in any cases. In order to improve tumour to
background ratio, some of these patients were
injected i.p. The results are encouraging.650 ABSTRACTS
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Immunotoxins as anti-tumour agents
E.J. Wawrzynczak & P.E. Thorpe
Imperial Cancer Research Fund, Lincoln's Inn Fields,
London, UK
Conjugates prepared by linking toxins to monoclonal
antibodies are cytotoxic to cells bearing the target
antigen. The toxins most widely used have been
plant proteins such as ricin, from the castor bean,
and abrin, from the jequirity bean. Each consists of
a B-chain, by which the toxin binds to galactose-
containing molecules on cell surfaces and an A-
chain, which kills the cells by inactivating
ribosomes. It is possible to link the intact toxin to
the antibody and block the galactose binding site(s)
on the toxin B-chains to prevent the immunotoxin
from binding to and killing non-target cells.
Alternatively, the A-chain can be attached directly
to the anti-tumour antibody via a disulphide bond.
A panel of immunotoxins was prepared from the
OX7 antibody against the mouse Thy 1.1 antigen
linked to the A-chains of abrin or ricin or to two
ribosome-inactivating proteins which act in a
similar fashion: Saporin from Saponaria officinalis
and Momordica charantia inhibitors. The in vitro
cytotoxicity of an immunotoxin did not prove to be
a good guide to its anti-tumour effect in vivo. Thus,
the anti-Thy 1.1-ricin A chain conjugate inhibited
protein synthesis in AKR-A lymphoma cells by 50%
(ID50) at a concentration of 2.7 x 10-1 M. This
conjugate extended the median survival time of
mice with lymphoma by 9 days, corresponding to
the killing of 99.9% of tumour cells. In contrast, the
anti-Thy 1.1-saporin conjugate, which had an ID50
of 6.7 x 10-1 M, extended the median survival time
by 24 days. This corresponds to killing of between
99.99% and 99.999% of AKR-A cells.
T-lymphocyte depletion of donor bone marrow in
human bone marrow transplantation
E. Gordon-Smith
Department ofHaematology, Royal Postgraduate
Medical School, london, UK
That donor lymphocytes, particularly the T-cell
subsets, are instrumental in provoking graft versus
host disease (GVHD) has been documented in
many animal models. The original descriptions of
GVHD showed that the graft versus host response
(GVHR) was dependent on immunologically
competent lymphocytes in the donor graft, a failure
of host lymphocytes to reject the graft and the
presence of a major histocompatibility difference
between donor and recipient. The severity of the
GVHR was proportional to the number of
immunocompetent donor cells transferred and to
the degree of histocompatibility difference. The
GVHR probably involves lymphocytotoxicity
directed against host lymphoreticular tissues.
GVHD is a consequence of this but is not
necessarily dependent on specific donor lympho-
cytotoxicity directed against the target organ.
Host factors are important in the development of
the disease. The further elucidation of the GVHR
which showed that mature T-lymphocytes were
responsible for the reaction and the suspicion that
immune reconstitution could occur after bone
marrow transplantation from lymphocyte precursors
in the donor marrow which would not provoke the
GVHR has led to many attempts to remove mature
T-lymphocytes from the donor marrow before
infusion. The urgency of the attempts to reduce
GVHD arose out of the observation that acute
GVHD and its complications was the major cause
of death related directly to bone marrow transplan-
tation and was the complication which limited the
use of transplantation to matched sibling donors.
SESSION 5 (Open Papers)
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Change in binding specificity of an anti-tumour
monoclonal antibody after chemical modification
S. Canevari, D. Mezzanzanica, R. Orlandi,
M. Ripamonti & M.I. Colnaghi
Istituto Nazionale Tumori, Milan, Italy
The use of monoclonal antibodies (MAbs) for in
vivo therapeutic approaches depends largely on
their specificity. During the characterisation of ricin
A chain-murine MAb conjugates, we found that the
binding specificity of a MAb raised against human
ovarian carcinoma (MOv2) seemed altered, whereas
its cytotoxic specificity remained unchanged. There-
fore, the binding reactivity of unmodified MOv2,
conjugate intermediate MOv2-PDP and MOv2-A
chain, was tested on 10 different histological types
of human tumour cell lines. These three reagents
bound with the two reference cell lines were tested
(the ovary carcinoma SW626 and the colon
carcinoma HT-29). The MOv2-PDP and MOv2-A
chain also reacted with 2 cell lines which wereABSTRACTS 651
unreactive with the unmodified MOv2 (the
melanoma MALME 3M and the breast carcinoma
MCF-7).
To elucidate the significance of these findings, the
following experiments were performed: cross
inhibitions between the unmodified and modified
MAbs; comparative absorption tests with relevant
and apparently irrelevant cell lines; biochemical
analysis of the target antigens. The results suggest
that after chemical modification the MAb MOv2
increases its binding activity, so that even low
numbers of antigenic sites which may be present on
apparently irrelevant cell lines can be detected.
Depression of glioma allografts by antibody-coupled
T cells
Th. Bilzer1, S. Aumann1 & D. Stavrou2
'Institute ofAnimal Pathology, University of
Munich, and 2Institute ofPathology, Clinicum
Bogenhausen, Technical University ofMunich, FRG
Allografts of experimental rat brain glioma in
immunodeficient mice were treated with T cells
coupled with the monoclonal glioma antibody
14ACI. The antibody has been produced by fusion
of splenocytes from glioma-hyperimmunized
BALB/c mice and the X63-Ag8.653 mouse
myeloma line. The antibody belongs to the IgG2a
isotype (Stavrou et al., 1983, Eur. J. Cancer Clin.
Oncol., 19, 1439).
T cells were collected from peripheral blood,
spleen and lymph nodes of normal healthy BALB/c
donors by depleting IgG-pos cells after Ficoll-
Hypaque flotation (Bilzer et al., 1982, Anticancer
Res., 2, 345). T cell-antibody binding was confirmed
by micro-ELISA prior to application.
Five million T cells franked with hybridoma
ascites were transferred on days 2, 4 6 and 12 after
tumour implantation. The mean tumour mass
determined in day 28 was 5.9g, whereas mice
treated with the antibody alone revealed 14.3g on
average. Untreated mice as well as mice treated
with normal T cells had to be killed between days
14 and 21 because of tumour size and perforation.
Results of T-cel depletion with CAMPATH-1 in
bone marrow transplantation (BMT) for chronic
granulocytic leukaemia (CGL)
J.F. Apperley1, J.M. Hows1, G. Hale2,
H. Waldmann2, E.C. Gordon-Smith1
& J.M. Goldman1
'Department ofHaematology, Royal Postgraduate
Medical School, London, and 2Department of
Pathology, University ofCambridge, UK
We have transplanted 27 patients with CGL using a
rat monoclonal antibody, CAMPATH-1, for T-cell
depletion. The patients can be divided into 'good
risk' (16 patients in chronic phase (CP)) and 'poor
risk' (two in second CP, three in acceleration, two
in blast crisis, one with busulphan induced aplasia
and three in CP from mismatched family donors).
Conditioning consisted of daunorubicin 60 mgm 2,
cyclophosphamide 120 mgkg-1 and TBI of 10-12
Gy in divided doses. Cyclosporine was given post-
BMT to 21 of 27 patients. Donor marrow was
treated with CAMPATH-1 ex vivo, and donor
serum was used as the source of complement. The
mean cell dose given was 2.7 x 108 kg-1 (range 1.3-
4.3) of the 'good risk' group. All are alive with
Karnofsky scores of 80-100% at 21-418 days.
Engraftment was satisfactory with the average
number of days to a neutrophil counts
>0.5 x 1091-1 being 21 (range 11-33). Acute
GVHD (Grade I-II) has occurred in only four
patients to date, and chronic GVHD in four of the
11 evaluable patients. Of the 'bad risk', four are
alive at 109-365 days. Three died of graft failure, 2
of idiopathic interstitial pneumonitis and 2 of CMV
pneumonitis. Acute GVHD (Grade II-IV) occurred
in 5 patients and chronic GVHD in 2 of the 4
patients surviving beyond 100 days. Graft failure
was seen in five patients and, despite further
conditioning and a second BMT without T-cell
depletion for these patients, satisfactory
engraftment has not been achieved in any case to
date. We conclude that: (1) T-cell depletion
successfully reduces the incidence and severity of
GVHD, but (2) the incidence of graft failure in
'poor risk' patients is high, and the chances of
achieving successful engraftment with a second
BMT are low.652 ABSTRACTS
Sensitivity of malignant lymphoid cells to ricin
A-chain immunotoxins
G. Laurent, P. Casellas, J.M. Derocq, P. Poncelet,
D. Dussossoy & F. Jansen
Centre de Recherches Clin-Midy Sanofi,
Montpellier, France
A total of 32 immunotoxins (ITs) have been
prepared coupling ricin A-chain with monoclonal
antibodies reacting with several differentiation
antigens expressed in the cell membrance of various
malignant lymphoid cells. Twenty-two anti-T, nine
anti-B, and one anti-HAL-DR ITs were evaluated
using a protein synthesis inhibition assay.
Measuring 14C-leucine incorporation, the Ligand
Enhanced Specific Activity (LESA) factor (Casellas,
P. et al., 1982, Int. J. Cancer, 30, 437) has been
estimated for each IT. This study showed that the
specific activity of ITs can differ from one class of
antigen to another, LESA factor varying from 10 to
106 in the presence of activators (NH4Cl or
monensin). Among anti-T ITs, CD5 and CD7 anti-
T ITs were found to be the most active (LESA
factor varying from 102 to 106) while four CD8 and
two CD3 anti-T ITs did not show any activity.
Anti-CALLA ITs had poor efficiency. Only two
out of nine anti-B ITs showed a certain level of
killing efficacy (LESA factor >103). Furthermore,
this study showed that the LESA factor can differ
within the same cluster of differentiation up to 4
log amplitude. Finally, this study suggests the
influence of both antigens and antibodies on the
cell-killing efficacy of ITs.
Abnn and ricin immunotoxins against melanoma.
Toxicity related to binding, internalisation and
processing
A. Pihl, A. Godal & 0. Fodstad
The Norwegian Institutefor Cancer Research,
Montebello, Oslo, Norway
Conjugates of abrin and ricin with 2 antimelanoma
antibodies, 9.2.27 and anti-p2lo, were purified as
described by Thorpe et al., Eur. J. Biochem., 1984,
140, 63). The abrin immunotoxins were far more
specific than the ricin conjugates, which were highly
toxic also to a number of non-melanoma tumour
lines. The 8 melanoma cell lines studied were 20 to
500 times more sensitive to the abrin than, to the
corresponding ricin conjugates. The melanoma lines
differed over a 250-fold range in their sensitivity to
the abrin conjugates. The differences could not be
accounted for by different levels of antigen
expression, which varied over a 12-fold range, but
largely reflected the associated differences, over a
4,000-fold range, in the sensitivity of cells to the
native toxins.
Comparisons were carried out with respect to
toxicity, binding, internalisation and degradation of
labelled conjugate and its moieties in 2 cell lines
with different antigen expression. Experiments in
which the cells were preincubated with lactose,
antibody, or both, suggested that the immunotoxins
may be taken up by two different routes and that
in cells of different sensitivity to the conjugates,
differences in rate of processing were more impor-
tant than differences in rates of internalisation.
Use of monodisperse, magnetic particles for removal
of B-lymphoma cells from human bone marrow
G. Kvalheim, 0. Fodstad, K. Nustad, A. Pihl
& S. Funderud
The Norwegian Institutefor Cancer Research,
Montebello, Oslo, Norway
Several approaches involving monoclonal anti-
bodies have been used in attempts to remove
tumour cells from bone marrow destined for
autologous transplantation (Ritz et al., 1982,
Lancet, 60, 1266; Muirhead et al., 1983, Blood, 62,
327; Treleaven et al., 1984, Lancet, i, 70). The
success of such procedures will depend critically on
the specificity and reactivity of the antibodies used.
Here we report on the removal of B-lymphoma
cells from human bone marrow using an improved
generation of monodisperse magnetic polymer
particles prepared by Ugelstad et al. and 3 B-Cell
specific monoclonal antibodies prepared in this
laboratory. The antibodies (ABI, AB2 and HH2)
were of the IgM type and were either physically
adsorbed or chemically bound to the particles. Four
different Burkitt lymphoma cell lines (Rael, Raji,
Bjab and Balm-1) were used. The tumour cells were
mixed 1:1 with human bone marrow and a 25-fold
excess of the charged particles and incubated in
RPMI medium at 4°C with frequent turning. After
30min the magnetic beads were removed by placing
the tissue bottles for 1 min on flat cobalt-samarium
magnets. The number of remaining tumour cells in
the supernatant was determined in a soft agar
assay. It was found that the procedure was capable
of depleting the tumour cells by up to 5 logs,
without serious effect on the marrow progenitor
cells, as measured in GM and GEMM assays.ABSTRACTS 653
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Antibody-drug conjugates
M.J. Embleton
Cancer Research Campaign Laboratories, University
ofNottingham, UK
In order to prepare active anti-cancer drug-
antibody conjugates a number of basic require-
ments must be met. The candidate antibody must
react selectively with tumour cells and localise to
tumour tissue in vivo, and must withstand chemical
substitution. The drug should be active against the
target cells, and its structure must include
chemically reactive sites distinct from functional
sites in order to allow attachment without loss of
anti-tumour activity. With these requirements
fulfilled, there is a limit to the number of drug
molecules which can be attached directly to the
antibody molecule without irreversibly destroying
its ability to bind to antigen but the molar ratio of
drug:antibody may be substantially increased by
the use of a highly substituted carrier molecule
instead of drug alone.
Using the above criteria, conjugates of an
anti-human osteosarcoma monoclonal antibody
(791T/36) have been prepared with the cytotoxic
drugs vindesine, daunomycin and methotrexate, the
latter including drug-carrier-antibody conjugates.
These conjugates were cytotoxic in vitro for tumour
target cells which express the 791T/36-defined
antigen, but were relatively non-toxic to non-
antigenic cells. In vivo, radio-labelled conjugates
localised to tumour xenografts in immune-deprived
mice, and certain conjugates had a significant
tumour-suppressive effect at doses containing
therapeutic levels of drug. The main advantage of
the conjugates was lack of toxicity to the murine
hosts at levels greatly exceeding the LD50 of free
drug. Drug-antibody conjugates appear to hold
promise for future clinical application.
Dosimetry ofradiolabelied antibodies
M.J. Myers & G.R. Hooker
Departments ofMedical Physics and Radiotherapy,
Hammersmith Hospital, London, UK
The accuracy of dosimetric calculations depends on
how well the distribution and time course of the
therapeutic radionuclide can be defined. A number
of studies carried out using different 1311 labelled
antibodies for treatment of the peritoneum,
pericardium, pleura and gliomas using intravenous,
intra-arterial and intracavitary administration has
enabled the kinetics of the labelled antibody in vivo
to be investigated and measured with a fair
accuracy. Problems still exist in accurately localising
the radionuclide and determining its volume of
distribution even on a macroscopic scale. A
comparison has also been carried out between pre-
and post-treatment behaviour of the radiolabelled
antibody so that a therapeutic regime can be
predicted from a study with much lower doses.
Examples of dosimetric studies, explaining the
methods of obtaining the data and the calculations
involved, both before and during therapy and over
the range of treatments and types ofadministration,
will be presented and the problems in calculating
the doses to the tumour and the rest of the body
will be discussed.
Clinical results with regional antibody-guided
irradiation
A.A. Epenetos
On behalfofHammersmith Oncology Group, Royal
Postgraduate Medical School and Hammersmith
Hospital, and Imperial Cancer Research Fund,
London, UK
Recently we described a new therapeutic method
termed regional antibody guided irradiation where,
instead of intravenously, antibodies were adminis-
tered regionally into body cavities for treatment of
regionally confined tumours.
Fifteen patients with ovarian cancer were treated
intraperitoneally with 131I-radiolabelled antibodies
HMFG1, HMFG2, AUA1, H17E2 given singly or
as a mixture. Toxicity (reversible diarrhoea, leuco-
penia and thrombocytopenia) was noted at higher
than 100 mCi activities. Most patients benefited
symptomatically and, furthermore, in 6 out of 9
patients with stage III and minimal residual disease,
a complete remission was achieved and maintained
for 3-18 months after treatment.
Antibodies were introduced intracavitary for the
treatment of malignant pleural effusions (20-100
mCi 1311). There has been resolution with no
evidence of recurrence in 6 out of 7 pleural and 3
out of 3 pericardial effucions. Two patients with
Grade IV glioma of brain unresponsive to other
therapies were treated by arterial infusions of radio-
labelled antibodies (A9, EGFR1) 45-102mCi 1311).
A sustained clinical improvement was noted.
In conclusion, regionally administered radio-
labelled antibodies (A9, EGFR1) (45-102mCi 131I).
A sustained clinical improvement was noted.
survival of some patients with malignant disease.654 ABSTRACTS
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Human monoclonal antibodies used in the study of
immune reponse in patients with cancer
P.B. Christensen, K. Erb, J.C. Jensenius
& B. Nielsen
Biomedical Laboratory, Institute ofSurgery, and
Medical Microbiology and Pathology Departments,
University ofOdense, Denmark
Human-human hybridoma technology has been
used in an attempt to study the humoral immune
reactions of colorectal cancer patients against their
tumours and the possible reactions also against
tumours from other patients.
Seven fusions have been done with lymphocytes
from lymph nodes from patients with colorectal
cancer, using the human B-lymphoma cell line
LICR-LON-HMy-2 as fusion partner. A total of
301 hybrids were obtained. Of these 27 react in
enzyme-linked-immuno-sorbent assay (ELISA) with
one or more colon cancer cell lines. One of these
hybridomas produces antibody which in immuno-
cytochemistry reacts with a panel of colon cancer
cell lines and melanoma cell lines but not with
normal human lymphocytes. When using immuno-
histochemistry we found that this antibody in
addition reacts with antigen present on autologous
and several allogenous colorectal cancers. The study
suggests that some patients generate an immune
response against their own malignant cells and that
the antigens also are expressed by tumour cells
from other patients.
Validity of non-invasive dosimetry for monoclonal
antibodies in humans
Nancy D. Hammond, P.J. Moldofsky, R.E. Exten,
R.A. Gatenby & G.J. Broder
Fox Chase Cancer Centre and Jeanes Hospital,
Philadelphia, PA, USA
Two non-invasive methods for quantitation of
absolute activity and determination of biological
clearance of Iodine-131 labelled F(ab')2 fragments
of mouse monoclonal antibody localised in lesions
and normal tissue by patients with metastatic colon
carcinoma have been evaluated. The quantitation
includes kinetic measurements of 1311 activity in
lesions, liver and total body, calculation of absolute
activity in lesions, liver and total body and the
resultant computation of dose (rads) to these
tissues. Absolute activity calculations were based on
computer-acquired conjugate views of the organs of
interest and also on a 'first pass' approximation of
activity administered to the patients. Measurements
of patient attenuation were individually determined
from 131I transmission scans. Patient tumour and
liver volume and thickness were calculated from
contiguous CT scan sections. For patients analysed,
mean tumour and liver volumes were 175.8 and
2018.4cm3 respectively with the patient attenuation
coefficients ranging from 0.088-0.127cm-1. The
ratio of tumour to liver activity reached a
maximum of 6.1 at 72h with tumour uptake
+0.01% of administered dose cm-. Tumour doses
of - 1 rad mCi-I administered were found for a
typical lesion of 5cm diameter. The dose to the
thyroid gland was calculated for 2 patient
populations; one receiving Lugol's solution only
at the time of 131I administration and the
other receiving Lugol's for 3 days prior to 131I
administration. No significant difference in
absorbed dose to the thyroid was found. Lastly,
< 10% error was found in utilising these
quantitative methods when' compared to
measurements made with a tissue equivalent
phantom. Comparison was also made to actual
well-counter assayed samples of malignant and
normal tissues obtained from CT-guided needle
biopsies or surgical specimens.
Cytotoxic monoclonal antibodies with tumour
specificity as immunotherapeutic agents for
metastatic (-I tract adenocarcinoma
J.Y. Douillard, J. Vignoud, C. Maurel
& H. Koprowski
U.211 INSERM, UER Medecine, Nantes, France
A cytotoxic monoclonal antibody of IgG2a sub-
class, namely 17 lA, was used as immunothera-
peutic agent in patients presenting with widespread
metastatic disease. Twenty patients were infused with
500mg 17 1A pre-incubated with autologous
peripheral blood leucocytes obtained at
leucophoresis. No serious side-effects were noticed
except in one patient receiving a second antibody
infusion. Ten patients got no clinical benefit from
17 lA immunotherapy and died of disease pro-
gression 7+4 months after therapy. In the
remaining 10 cases, disease evolution was impaired
after antibody therapy: 5 patients were stabilised
and 5 patients showed a decrease in measurable
tumour size after treatment. Mean follow-up for
these 10 patients is presently 12.5+5 months with 9
out of 10 still alive and in good general condition.ABSTRACTS 655
This initial therapeutic protocol seems to show
some therapeutic activity but should be confirmed
by larger studies.
Antibody-guided radiolocalisation and therapy for
neoplastic meningitis
H.B. Coakham, R.B. Richardson, S. Boume,
A.G. Davies & J.T. Kemshead
Departments ofNeurosurgery and Physics, Frenchay
Hospital, Bristol, and ICRF Oncology Laboratory,
Institutefor Child Health, London, UK
The problems of accessibility of antibody cells that
may interfere with efficient targeting against solid
tumours can be overcome by local infusion of
radiolabelled antibody in certain anatomical sites
(Epenetos et al., 1984, Lancet, ii, 1441).
We report the first use of a radiolabelled mono-
clonal antibody (MCA) to localise and treat neo-
plastic meningitis due to a pineal tumour. MCA
UJ181.4 which recognises an oncofoetal neuroblast
antigen was labelled with 1311 and infused into the
CSF with 125I-HMFG2 as control. The results of
immunoscintigraphy and radiolabelled antibody
kinetics in the CSF, blood and urine confirmed
specific localisation of the antitumour MCA, with
ratios of up to 30:1 specific/non-specific MCA
being obtained. On the basis of this data a therapy
dose of 870 MBq 1311 UJI81.4 was given intra-
thecally. This produced a marked clinical improve-
ment and the patient remains in remission. Our
results suggest that direct access of antibody to
tumour cells in the CSF pathways is likely to give
superior results compared with intravenously
injected antibody for solid brain tumours.
The use of second antibody to accelerate the
clearance of therapeutic doses of 1311 labelled goat
anti-CEA in patients
J.A. Ledermann, R.H.J. Begent, F. Searle,
A. Green, K.D. Bagshawe, M.G. Glaser
& R.G. Dale
CRC Laboratories, Charing Cross Hospital, London,
UK
In radiommunolocalisation, administration of free
second antibody directed against the antitumour
antibody accelerates the clearance of the latter from
the circulation and increases the tumour:blood ratio.
In radioimmunotherapy, higher doses of antibody
and radionuclide are used. The purpose of this
study was to investigate the effectiveness and safety
of second antibody administation for radio-
immunotherapy. Patients with unresectable colo-
rectal carcinoma received 50mCi of 1311
conjugated to a polyclonal goat anti-CEA
antibody. The second antibody (horse or donkey
anti-goat) was given in 2.5-5 times the amount of
the first antibody 24h later and the kinetics of the
clearance showed that the administration of the
second antibody was associated with a rapid
increase in the removal of antibody from the
circulation and the body. In one patient the
circulating level of 1311 labelled antibody fell from
40% of its initial value to 8% within 3h of the
administration of the second antibody. By 60h
<10% of the radioactivity remained in the body.
The tumour was localised using a gamma camera
and the radioactivity in a biopsy specimen of the
tumour was four times as great as the radioactivity
in the blood.
Therapeutic doses of radiolabelled antibodies
given to patients have been well tolerated. The
rapid clearance of radioactivity from the body
using the second antibody may allow higher doses
of radioactivity to be used safely and further
studies are now justified.
Demonstration of the presence of functional HMFG2
antibody and its specific determinant in metastatic
breast tnmours
A.B. Griffiths", N. Padmanabhan2, C. Lazarus2,
P.S. Sheppard2 & J. Taylor-Papadimitrioul
lImperial Cancer Research Fund, London, and
2Guy's Hospital, London, UK
The aims of the study were to image metastatic
breast lesions using radioiodinated tumour
associated monoclonal antibody HMFG2 whilst
gathering information about antigen expression and
antibody behaviour in vivo. Imaging was
unsuccessful.
The antibody was shown to retain its binding
properties after iodination (either 123I or 1311).
Circulating labelled antibody was shown to bind to
immunoblots of PAGE separated T47D cells in an
ELISA assay and by autoradiographs of the
immunoblots, a more sensitive assay. Up to 80% of
circulating radioactivity could be recovered on
immunoglobulin. Autoradiographs of PAGE
separated pleural effusion fluid and pleural effusion
cell extracts demonstrated the presence of labelled
intact HMFG2 antibody in the pleural effusion
fluid and also on pleural effusion cells.656 ABSTRACTS
Autoradiographs of PAGE separated immunoblots
of extracted cutaneous metastases demonstrated
intact labelled HMFG2 in the lesion. Circulating
HMFG2 antibody could be demonstrated, to bind
to its specific determinant on PAGE separated
immunoblots of the cutaneous metastatic tumour in
both an ELISA assay and autoradiography of the
immunoblots.
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A new sensitive miniature enzyme immunoassay using
p-galactosidase/anti p-galactosidase complexes
(GAG) for the analysis of solid phase bound antigens
H. Durbin, E. Milligan & W.F. Bodmer
Imperial Cancer Research Fund, London, UK
The use of ELISA in laboratory medicine and
research is now widespread. However, for situations
where target antigen or volume of test solution is
limited, the deficiency in existing systems of lack of
adequate sensitivity has led to the development of a
new extra sensitive micro ELISA.
Monoclonal antibodies to fl-galactosidase have
been made allowing the use of complexes in a
version of the unlabelled enzyme-antienzyme
system.
Test volumes of 5 or 10pI are incubated for 1 h
with antigen bound to 60 well Terasaki plates; this
may be whole cells 103/well. Two subsequent 1h
incubations, (a) with an antimouse bridging
antiserum, and (b) with GAG complexes are
followed by a 30min incubation with a fluorogenic
substrate. Fluorescence is detected and recorded on
a Leitz MPV Compact MT inverted microscope
linked to a HP85 bench computer which controls
the automatic scanning process and print-out. A
plate is read in one minute and lower levels of
10-6M of the substrate reaction product may be
detected. Alternatively, quantitative fluorescence
may simply be recorded by photography over UV
light. By combining the use of a monoclonal anti ,B-
galactosidase/,B-galactosidase complex with other
refinements such as automation, all-over improve-
ments, not least in sensitivity, have been achieved.
The expression of placental alkaline phosphatase by
normal and gynaecological malignancy tissue defined
by the NDOG2 monoclonal antibody
J.O. Davies, K. Howe & G.M. Stirrat
Department ofObstetrics and Gynaecology, Bristol
University, UK
A murine monoclonal antibody, designated
NDOG2, has been developed which recognises the
three common allelic forms of placental alkaline
phosphatase (PLAP). This antibody has been used
in an indirect immunoperoxidase technique to
demonstrate PLAP in normal fallopian tube,
endocervical and endometrial epithelia as well as
normal lung and thymus. Variable degrees of
reactive staining with NDOG2 have been found in
64% of 56 cystadenocarcinomas and in 25% of the
44 cystadenomas studied. In addition, 65% of the
17 endometrial carcinomas and 42% of 12 cervical
cancers also express this antigen but none of the 3
uterine sarcomas or 3 vulval carcinomas showed
any degree of staining.
The use of a serum assay, based on the NDOG2
monoclonal antibody, to predict the course of the
disease in patients with ovarian cancer
J.O. Davies, K.Howe, B.Randle, C.A. Sunderland
& G.M. Stirrat
Department ofObstetrics and Gynaecology, Bristol
University, UK
The NDOG2 monoclonal antibody, which reacts
withthecommonformsofplacentalalkalinephospha-
tase (PLAP), has been used to demonstrate reactive
staining in 65% of 56 ovarian cancers, predomi-
nantly serous cystadenocarcinomas (Sunderland
et al., 1984, Cancer Res., 44, 4496).
To assess the usefulness of this potential tumour
marker, NDOG2 has been used as the basis of two
serum assays. Assay I measures PLAP activity
whereas Assay 2 measures the NDOG determinant.ABSTRACTS 657
There was a close correlation between positive
reactive staining with NDOG2 and pre-operative
serum levels using both assays. Assay 1 proved to
be of predictive value in 12 out of 44 patients
studied and Assay 2 was of value, both in these
cases and in a further 8 patients. In an additional 7
cases, Assay 2 initially predicted the course of the
disease but subsequently fell, inappropriately, prior
to the patient's death.
Assay 2 offers potential in the management of
patients with ovarian cancer, particularly those with
serous cystadenocarcinomas. However, as NDOG2
recognises a tumour associated, as opposed to a
tumour specific, antigen, care should be taken in
interpreting the significance of a single elevated
result.
The use of monoclonal antibodies to ras-oncogene
product in the diagnosis of carcinoma of the colon
and rectum
N. Habib', H. Niman2, A. Thompson',
D. Kersten' & C. Wood1
'Department ofSurgery, Royal Postgraduate
Medical School, London, UK and 2Department of
Molecular Biology, Scripps Institute, La Jolla,
California, USA
The expression of c-ras oncogene has been demon-
strated in carcinoma of the colon and rectum. The
activated cellular ras-oncogene synthesizes a protein
(p21) with a point mutation at position 12. We
developed monoclonal antibodies against amino
acid sequences of p21 centred on this specific point
mutation.
Using the peroxidase-anti-peroxidase techniques
we stained sections from colorectal cancer using
monoclonal antibodies to p21. Staining was positive
in all tumour sections of 8 patients with colorectal
malignancies and negative in both proximal and
distal resection margins of colectomy specimens in
these patients. Monoclonal antibody binding was
found in both nucleus and inner side of the cell
membrane.
Staining of colorectal tumour tissue with
monoclonal antibodies against ras-oncogene pro-
ducts may open new avenues for immuno-
histological diagnosis.
Uses of monoclonal antibodies specific for the human
oncoprotein p62c-mYc in molecular biological and
clinical analyses
G.I. Evan, K. Sikora, J. Stewart, J. Watson
& R. Buick
Ludwig Institutefor Cancer Research and MRC
Clinical Oncology Unit, MRC Centre, Cambridge,
UK
We have prepared monoclonal antibodies specific
for human c-myc oncoprotein p62c-myc by
immunisation with synthetic peptides. These
antibodies have proved of immense value in
analysis of the cell biology of the c-myc onco-
protein, demonstrating the protein's subcellular
location and properties.
We have also used these antibodies in immuno-
histological analyses of normal and neoplastic
tissues, and in flow cytometric analyses of archival
histological material. Our data point to the future
uses of these reagents in diagnosis and prognostic
assessments from clinical specimens.
Detection of the c-myc oncogene product in colonic
polyps and carcinomas
J. Stewart, G. Evan, J. Watson & K. Sikora
MRC Clinical Oncology Unit and Ludwig Institute
for Cancer Research, MRC Centre, Cambridge, UK
The c-myc oncogene has been implicated in the
processes of normal cell proliferation and differen-
tiation. Elevated levels of c-myc mRNA and its
gene product (p62c-mYc), have been detected in a
variety of solid tumours and cultured cell lines. Its
precise role in normal cell function and in
neoplastic transformation and progression has yet
to be elucidated. We have used a monoclonal
antibody, raised by peptide immunisation, to
determine the distribution by immunoperoxidase
staining of the c-myc oncogene product in archival
specimens of colonic polyps and carcinomas.
Samples from 42 patients with colon carcinoma, 24
with benign polyps and 15 normal colon biopsies
were examined. Normal colon revealed maximum
staining in the mid-zone of the crypts, corres-
ponding to the zone of differentiation and
maturation. The staining was predominantly
cytoplasmic. Adenomatous polyps revealed the
most intense pattern of staining in areas of
dysplastic change. Colonic tumours showed a wide
range of staining. Well differentiated tumours
contained more cytoplasmic p62c-IYc than poorly658 ABSTRACTS
differentiated tumours. These findings suggest that
the c-myc oncogene product may play an important
role in the evolution of colonic neoplasia.
Demonstration of placental alkaline phosphatase
(PLAP) and tissue non-specific alkaline phosphatase
(AP) in normal lung tissue
D.E. Pollet, E.J. Nouwen, M.W. Eerdekens,
T.W. Briers & M.E. De Broe
Department ofNephrology-Hypertension, University
Hospital ofAntwerp, Edegem, Belgium
PLAP was assessed by an enzyme immunoassay as
reported by Pollet et al., 1985, Clin. Chem., 31, 41.
AP was quantified by a similar assay system
including an AP specific monoclonal antibody
(AP230). Tissue samples were obtained post
mortem after donor nephrectomy, at pneumectomy
or at the occasion of an induced abortion. The
presence of Nagao-type PLAP was assessed by
L-Leucine inhibition (1 mmol1-1).
Adult lung tissue contained a mean PLAP
activity of 78mUg-1 (range 3-181); this is 6.4%
(range 1-22) of the total alkaline phosphatase
activity. No L-Leucine sensitive PLAP activity
could be found in these extracts. The main alkaline
phosphatase found in adult lung tissue was tissue
non-specific AP as could be demonstrated by the
sensitivity to amino acids, L-p-bromotetramisole,
neuraminidase treatment and heat inactivation
analysis. Foetal lung tissue (n=5) between 11 and
15 weeks of gestation did not contain a substantial
amount (>2Ukg-1) of PLAP. The biochemical
results were confirmed by immunohistological
localisation of PLAP on the respiratory bronchioli
and alveoli, and by the histological localisation of
AP in the tracheal and bronchial epithelium, the
tracheal and bronchiolar glands, and the endo-
thelium ofsmall blood vessels.
Serum levels of hPLAP and CA125 in benign and
malignant disease and immunohistochemical evidence
for CA 125 hepatic uptake
M.W. Eerdekens, E.J. Nouwen, D.E. Pollet,
T.W. Briers & M.E. De Broe
Department ofNephrology-Hypertension, University
Hospital ofAntwerp, Edegem, Belgium
In a comparative study, human placental alkaline
phosphatase (hPLAP), CA 125 and CEA were
determined in sera of patients with ovarian (20) and
non-ovarian tumours (45), and in patients with
non-malignant disorders (126), using monoclonal
antibodies against these antigens. The latter
group consisted of 10 diabetic, 19 renal insufficiency,
50 chronic dialysis, 24 icteric non-cirrhotic, 9 icteric
cirrhotic and 14 cirrhotic nonicteric patients.
hPLAP and CA 125 had the same sensitivity (20%)
for non-ovarian tumours, whereas that of CEA was
45%. In ovarian cancer, the sensitivity was 45% for
hPLAP, 69% for CA 125 and only 10% for CEA.
hPLAP had the lowest false-positivity (2%) in
patients with non-malignant disorders (1 diabetic
and 2 patients on chronic dialysis). In contrast,
CA 125 and CEA were increased in 23% and 18%,
respectively, of patients with benign pathologies. In
this group, cirrhotic patients had the highest
prevalence (88%) of elevated serum CA 125 levels.
CA 125 was localised immunohistochemically in
normal liver tissue of a patient with a metastatic
poorly differentiated pancreatic adenocarcinoma
having increased serum levels of hPLAP, CEA and
CA 125. Positive CA 125 staining was observed
intracellularly in hepatocytic lysosomes and was
absent in Kuppfer cells. Normal liver does not
contain detectable CA 125 staining. This
observation is suggestive for uptake of CA 125 by
the hepatocytic asialoglycoprotein carrier
mechanism. This hypothesis also explains the
elevated serum levels of CA 125 in patients with
impaired liver function. The sensitivity of hPLAP in
detecting ovarian cancer is slightly inferior to that
of CA 125, but its specificity is much higher.ABSTRACTS 659
Monitoring advanced seropapillary anaplastic ovarian
cancer by deterninations of CA 125
T. Hdgberg1 & A. Hedin2
1Department ofGynaecological Oncology, University
Hospital, Linkoping, Sweden and 2Pharmacia AB,
Uppsala, Sweden
The clinical value of CA 125 as a marker in
advanced ovarian cancer during and after therapy
was studied.
In 26 patients with seropapillary or anaplastic
(FIGO histological group Ic or 5) ovarian cancer
FIGO stage III and IV, serum samples were drawn
and then frozen for later analyses before each
chemotherapy cycle, before second look operations
and at each visit during follow up. First sample was
taken at different phases of disease. Analyses were
carried out with kits from International CIS,
France.
Fifteen of 26 patients (60%) showed positive
marker (>35Uml-1) at any time. If patients
clinically not expected to show high marker are
excluded, 15/20 (75%) showed positive marker.
There were definite patterns over time depicting
tumour response during chemotherapy. There was a
correlation between pre-operative marker value and
findings during second look operations, although
there could be widespread cancer with a normal
marker value. In two cases relapsing during follow
up there was a lead time of at least 6.8 and 1
month respectively between high marker value and
clinically evident tumour.
It is concluded that CA 125 correlates well with
evolution of disease in -80% of the cases; could
perhaps be used as an early sign of sensitivity to
cytostatic drugs; correlates with findings at second
look, but cannot be used as a subsitute for
operation, and can signal a relapse before it
becomes clinically evident.
Human anti-mouse immunoglobulin responses in
patients receiving monoclonal antibodies
N.S. Courtenay-Luck, S. Needham, R. Moore,
M. Larche, B. Dhokia, M. Ritter & A.A. Epenetos
Departments ofImmunology and Radiotherapy and
Oncology, Royal Postgraduate Medical School,
London, UK
The use of mouse monoclonal antibodies in the
diagnosis and therapy of malignant neoplasms is
proving to be of great clinical interest. A conse-
quence of using mouse antibodies is stimulation of
a vast array of immunological responses including a
human-anti-mouse response.
Experiments carried out using patients' sera after
both a diagnostic and therapeutic injection of
monoclonal antibodies labelled with radioactive
iodine show quite clearly the presence of human
anti-mouse antibodies.
Screening of our patients' sera has been done by
employing two methods: (1) a modified enzyme-
linked immunosorbent assay, ELISA, and (2)
hybridoma targeting which employs the use of
antibody bearing hybridoma cell cytospins.
Our studies show that the reponse is anti-mouse
not anti-idiotypic and the response is greatest if the
interval between the first and second injections is
greater than 10 days, due to the mainly IgG
secondary immune response, and negligible if
patients are given the diagnostic and therapeutic
injections within 7 days of each other, hence
preventing the development of a large secondary
immune response.
Study of the expression of the HLA-DR antigen on
cloned melanoma cell lines with a potent monoclonal
antibody
S. Hallez, F. Vessiere, C. Lemoine, K. Willard,
T. Boon & P. De Meyts
ICP, Unite HORM 7524, and LICR, 75 and 74 av.
Hippocrate, Brussels, Belgium
We have produced a monoclonal antibody against
the class II MHC HLA-DR antigen. '25I-antibody
03-D7 binds irreversibly to the surface of DR+
lymphoblastoid cell lines. It binds to all DR+ cell
lines independently of haplotype. Scatchard plots
show an apparent affinity of more than 101OM-1.
The antibody binds in Western blots to the purified
,B chain HLA-DR. We used the monoclonal 03-D7
to investigate its binding to twelve different cloned
melanoma cell lines. Three cell lines did not show
binding of the 1251-monoclonal, while the nine
others showed binding with a great variation in the
number (3.4 x 105 to 1.17 x 107 sites/cell) and
affinity (2.9x 108 to 1.6x 101 M-1). This suggests
that the modality of expression of DR molecules on
the surface of melanoma cells may greatly vary.
The labelled monoclonal may be a useful tool in
positive identification ofmelanoma cells.660 ABSTRACTS
Immunohistochemical studies of mammary carcinoma
with the monoclonal antibody MC 211
C. Maurel, G. Aillet, M. Kremer, J.F. Chatal
& J.Y. Douillard
U.211 INSERM, UER Medecine, Nantes, France
Monoclonal antibody MC211 (IgA class) was
produced by hybridomas after immunisation of
BALB-c mice with membrane-enriched fractions of
human mammary carcinoma and breast cell line
MCF7. Using an immunohistochemical method,
with the avidin-biotin peroxidase complex, the
reactivity of MC211 MoAb was studied in
formalin-fixed paraffin embedded sections of
surgical specimens.
Twenty-five of the 27 mammary adeno-
carcinomas tested were strongly positive (50 to 80%
positive cells); the 2 others were weakly positive
(10% positive cells); one mammary endocrine
carcinoma was negative; non-breast
adenocarcinomas were tested; digestive carcinomas
were positive (7/7: colon, pancreas, stomach adeno-
carcinomas; 3/4 ovarian carcinomas were weakly
positive; the two pulmonary adenocarcinomas
tested were weakly positive;
The other tumours tested were negative: 3
endocrine tumours; 2 pleural mesotheliomas; 2
malignant melanomas; 3 sarcomas.
Therefore, MC211 monoclonal antibody seems
to be of interest in the diagnosis of adeno-
carcinomas and will be further evaluated in
immunohistochemistry for the detection of bone
marrow micrometastases from breast carcinomas at
the time of surgery and as radioimmunoimaging
agent for the diagnosis of lymph node involvement
and other metastases.
Monoclonal antibodies to liver F-antigen discriminate
between parenchymal and ductular epithelial cells in
adult human hepatic tissue
P.J. Higgins
Memorial Sloan-Kettering Cancer Center, New
York, USA
Hybridoma cell lines producing monoclonal
antibodies (MAbs) to F-antigen of liver were
prepared by fusion of NS-1 myeloma cells with
spleen cells obtained from CBA mice immunised
with saline extracts of BALB/c mouse liver. MAbs
reactive with F-antigen were selected by
comparative immuno-blot screening using electro-
phoretically separated proteins from BALB/c liver
and polyclonal anti-F-antigen sera. Immuno-
histochemical staining of paraffin-embedded and
cleared sections of normal adult human liver with
two such MAbs (I/2, I/5) defined epitopes of F-
antigen expressed only on lobular parenchymal
hepatocytes; bile duct epithelium, sinusoidal lining
cells, endothelial tissue and portal tract
mesenchymal elements were unreactive with these
MAbs. In a screen of 50 different malignant and
benign hepatic neoplasms of both murine and
human origin, MAbs 1/2 and 1/5 clearly
discriminated hepatocellular from ductular
carcinomas and adenomatous foci from bile duct
hyperplasia. It appeared that protease pre-treatment
of liver sections was necessary for maximum
immunocytochemical resolution of F-antigen with
1/2 and 1/5. Work is currently in progress to define,
using the current panel of MAbs, the controversial
origin of the 'oval' epithelial cell induced in the
livers of carcinogen-treated animals.
Monoclonal antibodies to prostatic specific antigens
F. Donn', W. Becker2, H. Becker', T. Bruns',
G. Griessonn' & A. Passargel
1Urologische Universitatsklinik, Hamburg, and
2Forschungsinstitut Borstel, FRG
In order to understand better the mechanism
involved in normal and abnormal prostatic growth,
we attempted to assess human specific antigens
defined by monoclonal antibodies. Balb/c mice were
immunised with membrane antigens hyperplasia
(BPH) and with protein from rat ventral prostate
cytosol that binds estramustine. This antigen was
obtained from Leo Research Laboratories and was
purified to homogeneity using chromatography on
DEAE-cellulose, Sephadex G-100, Octyl-Sepharose
CL-4B and polyacrylamide gel electrophoresis. The
screening method for the hybridoma supernatants
used immunoperoxidase stained frozen sections of
human tissues as well as the dot blotting method.
The antigens found by this method are of 3 classes:
a specific secretion product of the prostate which is
polyepithelial and stroma specific. The molecular
analysis was defined by 35S-methionine labelling
experiments of cultured prostatic cells and
subsequent SDS PAGE after immunoprecipitation
of supernatant by the selected hybridoma anti-
bodies. Except for the estramustine binding protein,
the functions of the antigens are still unknown and
are under investigation. They may be of value in
understanding the physiology of normal prostate,
benign hyperplasia and cancer.ABSTRACTS 661
Cross reactivity of the antimelanoma antibody 9.2.27
with human sarcomas and normal fibroblasts
A. Godal. 0. Bruland, 0. Fodstad, A.C. Morgan
& A. Pihl
The Norwegian Institutefor Cancer Research,
Montebello, Oslo, Norway
The antibody 9.2.27 directed against the 250K
melanoma-associated antigen (Morgan et al., 1981,
Hybridoma, 1, 27) has been extensively studied.
Although the antigen is present on some skin
cells (Ross et al., 1984, Cancer Res., 44, 4642),
it has not been identified on other tumour types
and has been considered specific for melanomas.
More than 90% of human melanomas express the
antigen (Oldham et al., 1984, J. Clin. Oncol., 2,
1235), and recently the application of the 9.2.27
antibody to the diagnosis and therapy of
melanomas has been intensively explored.
During a study of antisarcoma antibodies the
accidental observation was made that the 9.2.27
antibody binds strongly to sarcoma cells. Binding
to single cell suspensions was demonstrated by
indirect immunofluorescence and by radioactivity
measurements using labelled antibody, and binding
to cryostat sections was shown by peroxidase
staining. In vivo binding of radiolabelled antibody
to -sarcomas was demonstrated in tumour bearing
athymic mice as well as in patients with metastaic
sarcoma. Binding of 9.2.27 also occurs to pro-
liferating fibroblasts in primary cultures. Immuno-
precipitation studies demonstrated that the antigen
on fibroblasts and sarcoma cells is identical to that
present on melanoma cells.
Potential application of a new monoclonal antibody,
highly specific for human sarcomas
0. Bruland, 0. Fodstad, S. Funderud & A. Pihl
The Norwegian Institutefor Cancer Research,
Montebello, Oslo, Norway
The sarcomas represent a heterogeneous group of
tumours with multiple subtypes that are difficult to
characterise in detail. Recently, we have succeeded
in preparing a monoclonal antibody which is highly
specific for human sarcomas. Cells from a xeno-
grafted human osteosarcoma were used for
immunisation and antibody-secreting hybridomas
were screened by indirect fluorescence using unfixed
cells. Fibroblasts from several sarcoma patients
were used as negative controls. The new antibody,
TP-1 (isotype Ig2a), recognises a trypsin-resistant
protein of MW 105,000. When tested on acetone-
fixed cryostat sections, using a 3-step peroxidase
method, the antibody showed no significant binding
to a wide range of normal adult tissues, but bound
weakly to foetal kidney tubules. Forty-one non-
sarcoma malignancies of different histological types
were negative. In 29 sarcomas tested, positive
staining was obtained in 6/6 osteosarcomas, 5/5
malignant fibrous histiocytomas, 1/1 chondro-
sarcoma, 2/2 synovial sarcomas, 2/2 malignant
hemangiopericytomas and 3/5 unclassified
sarcomas. Three rhabdomyo-, 2 leiomyo- and 3
lipo-sarcomas were negative. The specificity profile
renders TP-1 a potentially useful reagent in the
histological identification and subclassification of
sarcomas. Using a radiolabelled F(ab')2 fragment
we have successfully imaged a human sarcoma
growing s.c. in nude mice.
Rat monoclonal antibodies to human uveal
melanomas
B.E. Damato1'2, W.S. Foulds2 & A. Campbell'
Departments of1Biochemistry and 2Ophthalmology,
University ofGlasgow, UK
Previous investigations into the immunology of
uveal melanomas have been limited by the lack of
well defined antigens.
Rat monoclonal antibodies to uveal melanomas
have been produced using fresh unfixed tissue. A
panel of these antibodies is being used to determine
the antigenic profiles of a bank of human uveal
melanomas by means of ELISA. Considerable
heterogeneity amongst primary tumours has been
revealed.
The antigenic profile of each tumour is being
correlated with the tumour cell type and patient
survival. It is envisaged that these studies will
enable clinically significant antigens to be identified.
Monocyte maturation index as a non-specific tumour
marker in cancer patients
Z. Rudolf, G. Sersa & G. Krosl
The Institute ofOncology, Ljubljana, Yugoslavia
The maturation index was compared with pertinent
clinical data (stage of the disease, course of the
disease, and response to treatment) in order to
establish clinical significance. The influence of
autologous sera was tested in cancer patients as
well as in experimental models (peritoneal
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macrophages from CBA mice). Monocytes from
peripheral blood were cultured in both autologous
and newborn-calf serum. Maturation index was
expressed as the percentage of monocytes placed in
culture which were present as adherent macro-
phages after 48h. Phagocytic capacity of CBA
mouse peritoneal macrophages was expressed as a
ratio of activity between cells cultured in patient
and healthy donors' sera. Maturation index (MI)
was in correlation with the stage of the disease in
malignant melanoma patients. The difference
between stage I and stage IV patients was
significant (8.2% vs 2.2%, P=0.01). Similarly dif-
ference was established between operated and
inoperable colorectal cancer patients (21.4% vs
5.1%, P=0.01). The difference between MI in
malignant melanoma patients with complete
response and progression of the disease was
significant as well (11.7% vs 2.2%, P=0.001).
Autologous sera inhibited the maturation process in
vitro in cancer patients. In an experimental system
autologous sera stimulated the phagocytic capacity
of mouse peritoneal macrophages when compared
with phagocytic of macrophages cultured in the
sera of healthy donors. The correlation between in
vitro monocyte maturation and clinical factors leads
to the conclusion the MI reflects the in vivo process,
and may prove useful as a marker of tumour load
or spread; it may be a sensitive monitor of the
effect of treatment, at least in the studied group of
patients.
Tumour heterogeneity and specificity of McAbs -
permanent challenges for in vivo application
K.S. Zanker & T. Lederer
Institutefor Experimental Surgery, Technical
University ofMunich, FRG
Even though the majority of tumours may be
monoclonal in origin, a 'clone is not forever' and
both phenotypic and genetic mechanisms create
extensive diversity within tumour cell populations.
In order to evaluate the advantage of specific
immune reactions of McAbs, we recently compared
McAb (Lederer, 1984, Br. J. Cancer, 50, 567) with
naturally occurring polyclonals concerning
complement-dependent cytotoxity and possible shift
of cycling cells to quiescence. Enlarging our studies,
polyclonals from two breast cancer patients were
purified (Armour Pharma, FRG) and tested for
complement-dependent cytotoxicity against two
allogenic human breast cancer cell lines. In
comparison, we focussed on a McAb, MGWe 15,
recognising an antigen of epithelial cells of
cancerous mammary gland. Interestingly, the
naturally occurring polyclonals showed
complement-dependendent cytotoxicity up to 22%
in vitro, the McAb failed. Both immunologic probes
shifted the human breast cancer into a dormant
stage and affected the transmembranal 75Se-
methionine traffic. In vitro incubation of the
polyclonals with peripheral lymphocytes suggested
an affinity directed against suppressorgeneic deter-
minants (OKT8), when monitored by double
fluorescence technique, using the Ortho-SystemB.
The McAb was highly specific for the epithelial
cells. In conclusion, under some instances, raised
McAbs might be 'super specific', without cytotoxic
effector function; however, to use such McAbs as
specific carriers for tumour toxic agents is an
enormous challenge.
Immunohistochemical studies of primary lung cancer
with HMFG1 and HMFG2 monoclonal antibodies
D.V. Skarlos, G. Tiniakos, N. Kalogeropoulos,
N. Papacharalambus, N. Nacopoulou,
A.A. Epenetos, & J. Taylor-Papadimitriou
Histopathology Department ofNIMTS Hospital and
Histopathology Department ofMedical School of
University ofAthens, Greece, Imperial Cancer
Research Fund and Royal Postgraduate Medical
School, Hammersmith Hospital, London, UK
Monoclonal antibodies HMFG1 and HMFG2
(Taylor-Papadimitriou, et al., 1981, Int. J. Cancer,
28, 17) raised against milk fat globule membranes
react with a broad spectrum of epithelial neoplasms
and are considered as epithelium specific, tumour-
associated antibodies.
Approximately 5gm formalin-fixed tissue sections
from 38 primary lung cancers (7 squamous, 5
adenocarcinomas, 4 large cell undifferentiated and
22 small cell carcinomas) ranging from well to
poorly differentiated types, were stained with
HMFG1 and HMFG2 mabs, using an indirect,
two-step immunoperoxidase method.
It has been shown that all the non-small-cell
cancers (NSCC) react strongly with the above
mabs, regardless of their degree of differentiation.
It is concluded, therfore, that these mabs could be a
useful tumour marker of NSCC.
On the other hand, the negative reaction of SCC
with these mabs could be related to the specific
origin of these tumours.ABSTRACTS 663
Immunohistochemical studies of periodontal disease
with TAL-IB5 monoclonal antibody
D.V. Skarlos, P. Augustatos, G. Tiniakos,
T.A. Adams & A.A. Epenetos
Pathology Department, NIMTS Hospital, Athens,
Greece, Imperial Cancer Research Fund, London,
and Royal Postgraduate Medical School and
Hammersmith Hospital, London, UK
TAL-IB5 is a monoclonal antibody which stains all
cell types known to express HLA-DR. This
antibody works well on formalin-fixed tissue
sections.
Using an indirect immunoperoxidase method on
frozen or formalin-fixed tissue sections from 24
patients with periodontal disease, it has been shown
that TAL-IB5 monoclonal antibody did not stain
the lymphocytes which infiltrated the gingivae.
Therefore, this indicates that lymphocytes of the
gingivae in periodontal disease are not of B-cell
origin. Furthermore, using monoclonal antibodies
specific for T-lymphocytes, we showed that
periodontal disease lymphocytes bear T-suppressor
markers (OKT-8, ORTHO). This could be related
to an attempt of the host to eliminate the
immunological process.
Blockade of the galactose-binding sites of ricin by
photoaffinity-labelling
H.-J. Thiesen', M. Brenken2, L. Hanke2,
H. Paulsen2 & R. Arndt1
1 Urologic University Clinic, and 2Institute of
Organic Chemistry and Biochemistry, University of
Hamburg, FRG
The cytotoxic action of A-chain conjugates is
accelerated or enhanced in the presence of free B-
chain or antibody B-chain conjugates. For in vivo
use, the galactose-binding sites of ricin B-chain have
to be blocked in order to diminish their binding to
galactose residues on non-target cells.
p-Azidophenyl-,B-D-Galactopyranoside and p-
Azidophenyl-fl-D-Lactoside were synthesised and
added to ricin recently repurified by Bio-Gel A
chromatography. Photolysis was carried out at
254 nm. After modification, the low molecular
reactants were separated by ultrafiltration.
Modified ricin could be separated from unreacted
ricin by Bio-Gel A chromatography. The elution
pattern revealed a slightly retarded motion of
modified ricin down the column. Efficiencies of
inhibition of the ricin fractions were compared in
cell assays in the presence of lactose. The results
show that the photoaffinity-labelling significantly
reduces the non-specific binding to galactose
residues. The modified ricin show similar toxicities
as unreacted ricin in the presence of lactose
(100mM).
If the degradation of ricin due to photolysis at
254nm can be reduced by introducing nitrogroups
into the phenyl-ring which photolyse at higher
wavelengths, higher yields of modified ricin should
be obtained.
In the future, the best approach to obtain ricin
lacking galactose binding sites would be the
recombinant DNA technique of site-directed
mutagenesis.
Removal of B-lymphoma cells from human bone
marrow using abrin immunotoxins
0. Fodstad, G. Kvalheim, A. Godal, S. Funderud
& A. Pihl
The Norwegian Institutefor Cancer Research,
Montebello, Oslo, Norway
Autologous bone marrow transplantation following
supralethal treatment with chemotherapy and
irradiation is a new approach to the management
of B-cell lymphomas. The high frequency of bone
marrow infiltration with lymphoma cells has
promoted attempts in several laboratories to
selectively eliminate the lymphoma cells by treat-
ment of the bone marrow ex vivo, by using proce-
dures involving monoclonal antibodies.
Here we report on the use of 2 different immuno-
toxins for purging bone marrow of lymphoma cells.
Whole abrin was conjugated to the antibodies AB3
(anti-HLA DR) and EOI (anti-common leukocyte
antigen). Normal human bone marrow was mixed
1:1 with each of 4 different B-lymphoma cell lines
and incubated with the immunotoxins in RPMI
medium containing 10% FCS and 0.1 M lactose for
2h at 37°C. The tumour cell kill, as judged by
colony formation in a soft agar assay, was in excess
of 2 logs at immunotoxin concentrations
(100ngml-1) that did not affect the clonogenicity
of the bone marrow progenitor cells in GM and
GEMM assays. Addition of monensin enhanced
strongly the tumour cell kill without enhancing the
effect on the normal bone marrow cells.
Experiments are in progress in which the above
procedure is combined with the use of antibody
absorbed to monodisperse magnetic polystyrene
particles.664 ABSTRACTS
Drug-antibody complexes for immunotherapy
G.A. Pietersz, J. Kanellos, M. Smyth
& I.F.C. McKenzie
Research Centerfor Cancer and Transplantation,
Department ofPathology, University ofMelbourne,
Parkville, Australia
To improve the specificity and efficiency of chemo-
therapeutic agents, three different drugs
(Adriamycin - Ad; Methotrexate - MTX; and
Chlorambucil - CBL) were covalently coupled to
monoclonal antibodies with specificity for cell
surface antigens. The coupling procedures were
carefully monitored, and optimised for maximum
recovery of protein, antibody and drug activity.
The results fell into three different groups: (a)
Adriamycin coupled (with difficulty) by the
iodacetyl derivative produced conjugates with 8-10
Ad molecules per antibody molecule. On testing in
vitro and in vivo the conjugates were highly specific
and active, but considerably less toxic than free
adriamycin (although more specific); (b) MTX,
activated by N-hydroxysuccinimide, led to conju-
gates containing 13-15mol of MTX per antibody
molecule. Again, these were highly specific and
acted both in vitro and in vivo; (c) CBL coupled
using the same method as for MTX, led to 35
residues of CBL per monoclonal antibody molecule,
with good retention of both drug and antibody
activity. The CBL conjugates were, again, highly
specific, but in addition were at least 6 times more
toxic than free CBL. This is one of the first
examples where antibody-drug conjugates are more
active than free drug - and this conjugate could
eradicate tumour cells grown in ascites form in
mice. Thus carefull attention to drug coupling
procedures to give high drug/antibody ratios can
lead to production of toxic and specific agents for
targeting.
In vitro treatment of colorectal cancer cells with
anti-p21
N.A. Habib, H.L. Niman, A. Thompson,
B. Fermor, M.O. Symes, R.C.N. Williamson
& C.B. Wood
Department ofSurgery, Royal Postgraduate Medical
School, London, Department ofSurgery, Bristol
Royal Infirmary, UK and Department ofMolecular
Biology, Scripps Institute, La Jolla, California, USA
Proto-oncogenes are involved in normal cell
growth. During malignant cell transformation they
become activated oncogenes and may produce
growth factors. C-ras oncogene situated on
chromosome 12 is specifically expressed in
colorectal carcinomas. To test their potential
therapeutic role, monoclonal antibodies against
oncogene protein products were applied to human
cancer cells obtained from 3 fresh colonic
specimens and maintained in cell culture. The
antibodies used were developed against specific
amino acid sequences of c-ras oncogene. Colonic
cancer cells were exposed to the antibodies for 24h
and labelled with radioactive selenomethionine for
a further 24h to determine RNA synthesis.
It was found that anti-ras monoclonal antibodies
caused marked inhibition of RNA synthesis by
cultured human cells obtained from all 3 patients
with colorectal cancer. The percentages of isotope
uptake in treated cells were 60% (73/129 c.p.s.),
24% (138/569) and 17% (25/150) of the uptake by
untreated cultured cells (control). By contrast
monoclonal antibodies against epidermal growth
factor caused no such inhibition, thus confirming
the specific action of ras-oncogene antibodies on
colonic carcinoma cells. The widespread expression
of oncogenes and their encoded proteins in human
malignancies could provide appropriate therapeutic
targets.
High efficiency antibody iodinations with
N-bromosuccinimide
S.J. Mather
Imperial Cancer Research Fund, London, UK
The oxidising agent N-bromosuccinimide (NBS) has
been investigated as a potential iodinating agent for
monoclonal antibodies. A variety of antibodies and
antibody fragments have been iodinated with
isotopes 1251 and 123J. By tailoring the amount of
NBS to the amount of iodine used, labelling
efficiencies of the order of 95% have been obtained
using small quantities of NBS.
Immunoreactivity of labelled antibody (HMFG2)
has been tested by ELISA after prolonged exposure
(3h) to NBS without any observable loss of antigen
binding.
The achievement of such labelling efficiencies
may eliminate the need for subsequent purification
procedures. This will be particularly useful in high
activity iodinations for antibody-guided radio-
therapy.ABSTRACTS 665
Choice of chelate for linking radionuclides or stable
nuclides to monoclonal antibodies
S. Dass, B. Arvind, G.K. Chaturvedi
& D.K. Hazra
Department ofChemistry, DEI Dayalbagh, Agra,
and S.N. Medical College, Agra, India
A variety of agents have been suggested for linking
radionuclides to immunoglobulins for radioimmuno-
detection (RID) and possibly radioimmunotherapy
(RIT) and this can be extended to stable elements
such as Gadolinium (Gd) for Nuclear Magnetic
Resonance (NMR), Boron for neutron activation,
and Europium for in vitro fluorescence assays.
These agents include derivatives of EDTA, DTPA,
Deferoxamine, CEDTS, Dextransandalbuminbenzo-
quinones, etc. Of these, five agents have been
evaluated, viz. bicyclic anhydrides of DTPA and
EDTA, monocyclic anhydride of DTPA, carboxy-
carbonic anhydride of DTPA and Deferoxamine
using both 99mTc and 113mln as well as stable
analogues of 99mTc, i.e. Mn and Re. Among these,
cyclic anhydride of DTPA was found to be most
useful by reasons of its ease of preparation and
characterisation. long shelf life, existence of three
nitrogen atoms for efficient linkage to metals and
rapid quantitative linkage to immunoglobulins with-
out alteration in their biological behaviour. The
other attractive agent was Deferoxamine which is
easily available and does not abstract Ca+2 and
Mg+2 ions present in the biological milieu. The
problems posed by competing netal ions during the
synthesis are emphasised.
Selection of radionuclide for radioimmunotargeting:
An Indian perspective
D.K. Hazra, S. Dass, A.K. Shukla, S. Saran,
M. Kumari, R.N.L. Srivastava, V.L. Lahiri
& R. Singh
S.N. Medical College, Agra, India
Monoclonal antibodies can be tagged with a variety
of radionuclides for radioimmunodetection (RID) or
radioimmunotherapy (RIT) either directly or
through bifunctional chelating agents. The require-
ments for RID (pure gamma emission of energy
suitable for gamma camera imaging or positron
emitting for double photon imaging) are distinct
from those for RIT (high LET radiation - alpha,
energetic beta or Auger electrons). Further, the
radioisotope should have a shelf life permitting
visualisation or therapy over the biological time
course of accumulation of monoclonal antibody in
the tumour, i.e. one to three days, and its daughter
products should not be undesirable. Temporal
subtraction of early from late images or dual
isotope subtraction of non-specific accumulation to
reveal specific localisation is possible in RID but
not in RIT. In India the non-availability of
cyclotron produced radionuclides and the limited
neutron flux in the existing reactors impose
constraints on the choice of radionuclides, 123I and
"'In being obviously ruled out. This has led us to
examine a large number of candidate radionuclides
both for RIT and RID considering also the half-life
of the radionuclide or its generator parent so as to
permit transport from Bombay to our centre and
adequate in vivo follow-up thereafter. These will
now be experimentally evaluated.
Human tumour xenografts in immunosuppressed
mice for evaluating monoclonals
S. Saran, M.C. Agarwal, B.R. Elhence, K. Singh,
I.P. Elhence, S. Khandelwal, R.N.L. Srivastava,
M. Kumari, S. Dass, D.K. Hazara & V. Lahiri
S.N. Medical College, Agra, India
Human tumour xenografts possess distinct
advantages as compared to chemical/viral induced
or spontaneous animal tumours for evaluating
monoclonal antibodies for clinical use. Nude mice
widely employed for such studies are difficult to
maintain and also provide an extremely artificial
environment for the tumour xenografts. We have
used a variety of immunosuppression regimes (com-
bination of irradiation, corticosteroids, cyclophos-
phamide and cytosine arabinoside) to achieve
successful xenografts from human breast carcinomas
as well as thyroid carcinomas and Ewing's sarcoma,
both directly and after preliminary culture in vitro.
The histology and antigenic expression of these
xenografts has been compared with that of parent
tumours as well as in vitro tumour explants using
monoclonal antibodies and model scanning
experiments have been performed. It appears that
they can conveniently be used to choose
appropriate antibodies for clinical use in radio-
immunodetection (RID) or radioimmunotherapy
(RIT).666 ABSTRACTS
Imaging of adenocarcinoma in rats with 125I Mab
against carcinoma associated ganglioside antigen
J. Gretarsdottir', L. Jakobsson', S. Matteson',
S.B. Homberg2, Lo Hafstrom2, L. Lindholm3,
B. Karlsson4 & 0. Nilsson4
Departments of'Radiation Physics, 2Surgery,
3Medical Microbiology and 4Neurochemistry,
University ofGothenburg, Sweden
Two monoclonal antibodies raised against human
carcinoma associated ganglioside antigens have
been used for experimental immunoscintigraphy.
The C50 MAb (IgM) reacts with two ganglioside
structures, i.e. Lea active pentaosylceramide (SiLea)
and sialyted lactotetraosylceramide, and the C241
MAb (IgGI) reacts with only SiLea.
MAb C50 and C241 were iodinated (1251) using
the lodobead method. Experimental colonic
carcinoma containing SiLea antigen was trans-
planted as cell suspension on 200g Wistar Fu rats.
Different sized tumours were located in leg muscles,
back subcutaneous tissue or liver. The animals were
anaesthetised and injected with 2 ug MAb i.v.,
activity 0.2MBq. Gamma camera images were
registered 1-72h after injection. Blood samples
were drawn at different intervals. Plasma
components were separated by exclusion chromato-
graph and radioactivity was measured in the
fractions. Tumour and organ activities were
measured after the animals were sacrificed.
Biological half-time in the whole body was 14h
for C50 and 100h for C241 (IgG). C50 tumour/
blood ratio was 0.2-0.8 at 48h, tumour/liver ratio
was 0.1-1.2 C241 tumour/blood ratio was 0.5-1.4
at 72h and tumour/liver 1.0-9.8. Column
separation of plasma showed at 24h 88% of 1251
activity bound to MAb, at 48h 84% and at 72h
73%. MAb C50 and C241 show tumour/blood
ratios that are equal to other MAb used for
immunoscintigraphy.
A comparison of radio-iodinated monoclonal
antibody AUA1 with indium-111 radiolabelied AUA1
and iodine-125 labelled F (AB')2 fragments of AUA1
in vivo
D. Snook', G. Rowlinson2, H. Durbin3, P. Blake',
F. Brady2, W.F. Bodmer3 & A.A. Epenetos'
'Royal Postgraduate Medical School and
Hammersmith Hospital, London; 2MRC Cyclotron
Unit, Hammersmith Hospital, London and 31mperial
Cancer Research Fund, London, UK
The human cervical carcinoma xenograph (HN16)
was used as an in vivo experimental model to study
the immunolocalisation of the monoclonal antibody
AUA1. The organ distributions of '251-AUAI and
"IIIn-AUA1 were compared. "'IIn-labelled
antibody produced greater tumour to normal organ
ratios than '25I-labelled antibody with the
exception of liver and kidney.
In a separate set of experiments, '25I-labelled
F(ab')2 fragments of AUA1 when compared with
whole AUAI produced better tumour to normal
organ ratios due to the rapid blood clearance of the
fragments.
F(ab')2 fragments of monoclonal antibodies offer
significant promise for tumour imaging and
possible therapy.
Indium "'In labelled monocolonal antibody to
placental alkaline phosphatase is of clinical value in
the detection of neoplasms oftestis, ovary and cervix
A.A Epenetos', T. Pawlikowskal, D. Snook',
G. Hooker', R. Begent2, H. Durbin3,
R.D.T. Oliver4, W.F. Bodmer3 & J.P. Lavender'
'Royal Postgraduate Medical School and
Hammersmith Hospital, London; 2Charing Cross
Hospital, London; 3Imperial Cancer Research Fund,
London, and 4Institute of Urology, London, UK
Indium-1Il labelled monoclonal antibody (Hi7E2)
against placental type alkaline phosphatase (PLAP)
and testicular placental-like alkaline phosphatase
was used in a prospective study of radioimmuno-
scintigraphy of 15 patients known or suspected to
have germ cell carcinoma of testis or carcinoma of
ovary or cervix. Good quality images of neoplastic
lesions were obtained in the majority of patients
with active disease. In two patients with normal
conventional radiology, antibody guided imaging
located the site of microscopic disease, thus aiding
surgical lymphadenectomy. No false positive
localisation was seen in patients with PLAP-
negative tumours or sites of inflammation such as
lung abscess.
This method appears to be a potentially
important new adjunct in the diagnosis, staging and
monitoring of disease status in patients with PLAP-
positive neoplasms such as testicular, ovarian and
cervical cancer.ABSTRACTS 667
Placental-type alkaline phosphatase detection by
monoclonal antibody (H317): Application in ovarian
cancer recurrence
P.J. McLaughlin', M. Critchley2, P.M. Tromans3,
I.W. McDicken4 & P.M. Johnson1
Departments of 'Immunology; 2Nuclear Medicine;
3Obstetrics & Gynaecology and 4Pathology,
University ofLiverpool, Liverpool, UK
Placental-type alkaline phosphatase (PLAP) is an
oncodevelopmental marker often found in ovarian
tumours of epithelial origin. In the present study, a
murine IgGI monoclonal antibody (H317) has been
used to measure circulating PLAP in plasma and
tumour tissue extracts using a specific enzyme
(McLaughlin et al., 1983, Clin. Chim. Acta, 130,
199) and also in fixed tissue sections using H317 in
a peroxidase-anti-peroxidase staining technique
(McDicken et al., 1983, Int. J. Cancer, 32, 205).
This monoclonal antibody was also used in
antibody-guided in vivo radionuclide imaging in
patients after removal of a primary tumour. Of 18
patients suspected of ovarian secondaries, 11
showed focal increased abdominal uptake of the
radiolabelled monoclonal antibody of whom 2 also
showed diffuse increased abdominal uptake. There
was a large 'cold' lesion visible in one patient,
confirmed at survey as a cystic tumour. There were
6 normal scans. Unsuspected tumour recurrence
was identified in 3 of the 8 clinically clear patients.
Detectable plasma PLAP was found in 6 of 13
patients, and 5 of the 6 available tumour tissue
extracts contained PLAP. PLAP was demonstrated
in 5 of 11 fixed tumour tissue sections by immuno-
histology.
The radioimmunolocalisation technique using
H317 usefully detected tumour recurrence in some
ovarian cancer patients. Although plasma PLAP
was only detected in 46% of patients, its presence is
known to be highly indicative of a tumour as no
healthy non-pregnant individuals express the
circulative H317-reactive form of PLAP. This is the
case even in cigarette smokers (McLaughlin et al.,
1984, J. Clin. Pathol., 37, 826).
Primary hepatoceliular carcinoma localisation using
a radiolabelled monoclonal antibody
N.I. Markham
Ludwig Institutefor Cancer Research, Cambridge,
UK
A rat monoclonal antibody, YPC2/38.8, was
selected from a panel of antibodies derived by
immunising rats with fresh human colorectal
carcinoma. It was found to bind to a 30,000 dalton
protein present on the cell surface of normal colon
and liver. This protein was increased ten-fold on
primary hepatocellular carcinoma (PHC) cells.
After labelling with 131I, YPC2/38.8 was shown to
localise human PHCs grown as xenografts in
immunosuppressed mice. Eighteen patients with
known or suspected PHC were given lmg of
purified antibody labelled with 1 mCi of 1311 by
slow i.v. injection. In seven out of eight patients
with PHC arising in non-cirrhotic livers, good
tumour images were obtained on gamma camera or
rectilinear scans. In seven patients who had
developed PHC on the background of established
hepatic cirrhosis, no tumour images were seen.
Three patients showed no localisation but diagnoses
other than PHC were eventually established.
Subsequent studies revealed that the 30K antigen
recognised by this antibody was present in
increased quantity on PHC cells and the
regenerating liver cells in cirrhosis. We conclude
that YPC2/38.8 may have potential for the selective
targeting of drugs or toxins in patients with PHC
arising in a liver unaffected by significant
parenchymal disease.
Detection of unknown metastases using 9"'Tc or "'In
labelled F(ab')2 fragments of a moab in 76 patients
with melanoma
G. Paganelli"2, P. Rival2, G. Cacciaguerral,
G. Landil, V. Tison', M. Marangolo'
& A. Amadoril
1Istituto Oncologico Romagnolo, Italy and
2Servizio di Medicina Nucleare, Ospedale M.
Bufalini, Cesena, Italy
Seventy-six patients with stage I-IV malignant
melanoma were studied with 991Tc or "'In-labelled
F(ab')2 fragments of MoAb 225.28S (Sorin-
Biomedica). Seventy-five per cent of previously
detected metastases were detectable by
immunoscintigraphy. Immunohistology of biopsied
tissues confirmed the specificity of antibody. In 26
out of 76 patients, unsuspected positive findings
were seen. These findings were divided into two
groups:
(1) metastases detectable with conventional
techniques performed at the same time as
immunoscintigraphy (63%)
(2) metastases not detectable by other methods
but confirmed by surgical investigation or by follow-
up 3-8 months after antibody scanning (73%).
There was only one false positive scan, caused by
free 99mTc in the gut.668 ABSTRACTS
Localisation of tumours with "'Tc-monoclonal
antibody complexes
G.A. Pietersz, J. Kanellos, J. Baldas, J. Bonnyman
& I.F.C. McKenzie
Research Centrefor Cancer and Transplantation,
Department ofPathology, University ofMelbourne,
Parkville, Victoria, Australia
Although technetium-99m has ideal physical
properties for imaging, little use has been made of
the radionuclide for labelling monoclonal
antibodies - presumably because of labelling
difficulties. However, recently a new method for
preparing 99mTc radiopharmaceuticals based on
substitution reactions of 991TcNCI4 has been
described. This agent can be prepared in the dry
form without the presence of any contaminating
metal ions and leads to the formations of Tc
chelates in the presence of a Tc nitrido group.
Taking advantage of the unique properties of this
compound, we decribe a simple method of labelling
Mg quantities of monoclonal antibodies for
evaluation of the clinical usefulness of 99mTcN-Mab
complexes as diagnostic reagents.
The stability and activity of these complexes were
examined in vitro with a simple binding assay wich
involved antigen positive and antigen negative cells.
The complexes were shown to be highly specific
and would bind antigen positive cells 10 times
greater than antigen negative cells.
In an in vivo experimental model
(BL6 xBALB/c)Fl mice carrying palpable ITT(l)
75NS tumours (0.4-1.5cm diameter) were injected
i.v. via tail vein with either of two monoclonal
antibodies labelled with 99mTcNCl4. Mice were
either scanned with a gamma camera or their
tissues were removed and the localisation of
radiolabelled antibody calculated as cpmg-1 of
organ, results were calculated as a ratio of the
tissue to blood distribution. The studies showed
that specific localisation had occurred. Tumours
(4mm) could be successfully imaged without the
need for background subtraction.
Treatment of advanced B-cell lymphoma with
monoclonal anti-idiotype antibodies
A. Hekman, A. Honselaar & E.M. Rankin
Division ofImmunology, The Netherlands Cancer
Institute, Amsterdam, The Netherlands
Four patients with non-Hodgkin's lymphoma have
been treated with mouse monoclonal antibodies
(moab) directed against the idiotype of the tumour
immunoglobin. Two moabs were IgG2a and two
IgGl. Single dose of 10mg to 1200mg were infused
over 4 to 48h in an escalating schedule reaching
total amounts of 3.8 to 4.8 g over periods of 3
weeks to 2 months. Patients were monitored for
binding of moab to malignant cells in different
sites, serum moab level, level of serum idiotypic Ig
if present, clinical response, side effects and anti-
mouse antibodies. Infusion of anti-idiotype resulted
in transient falls in circulating lymphocyte counts
and/or temporary removal of circulating idiotype.
Binding to peripheral tumour cells was seen before
complete clearance of free idiotype. After doses
exceeding saturation of cells and removal of free
idiotype, free moab was detected in the serum of 3
patients, but not in the fourth. Binding of moab in
vivo to tumour cells in lymph nodes, bone marrow
and ascites could be demonstrated. Overall
therapeutic effect was minimal, 3 patients showed a
slight, 10%, decrease in lymph node size, in 1
patient the tumour was unaffected. There was no
evidence of modulation in 2 patients. In one case
the circulating tumour cells showed a reversible
decrease in antigen density, but never became
idiotype negative. One patient showed an abrupt
increase in modulation in vivo after 2 weeks of
treatment. Experiments in vitro showed that this
was due to the removal of a discrete subpopulation
of smaller, nonmodulating tumour cells. Apart
from one episode of acute hypotension, side effects
were generally minimal; there was no decrease of
kidney or liver function. None of the patients made
anti-mouse antibodies.